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ABSTRACT 
Previously reported differences in transfusion practices suggest that transfusion 
protocols and clinical transfusion decisions may often be inappropriate. To 
change and monitor practices requires a follow-up system. A healthcare-
integrated data-gathering system could provide the required information about 
blood use. The purpose of this observational study was to create a follow-up 
system for blood use and to gather information about transfused patients and 
transfusion practices in Finland. 
Data came from ten Finnish hospital districts (five university and five tertiary-
care hospital districts) between the years 2002 and 2005. The collection process 
involved combining data from electronic medical records applied for five 
different purposes: blood banking task-management, blood bank management, 
and laboratory test collection, as well as operating room purposes and a 
description of hospital visits. This information was combined from these 
electronic systems by use of personal identification numbers and data expressed 
as hospital episodes. 
Validation of the combined data proved sufficient for study purposes. For 
example, 97% of adult blood products agreed with supplier’s sales figures. 
Variation in blood-use practices still existed between hospitals. For example, the 
percentage of red blood cell (RBC) receivers ranged in Finnish hospitals from 
12% to 57% during primary knee-arthroplasty surgery. Finnish blood recipients 
were generally elderly; over 50% of those transfused were over 65. The most 
typical blood-transfused patient was an over 65-year-old woman receiving 2 
units of RBCs. About 10% of all blood products were transfused to children. RBC 
products and fresh frozen plasma (FFP) were usually transfused in pairs (such as 
in two-four-six units). Most (over 60%) of the transfused FFP went to surgical 
patients. One-fourth of FFP-transfused surgery patients suffered from blood 
circulatory system diseases. In over 30% of FFP transfusions, plasma was given 
without any guidance from coagulation tests. In Finland, about 100 FFP units 
and 400 RBC units were transfused during 1 000 hospital visits including 
surgery. Among moderately anemic parturients, transfusion of 0 to 2 units of 
RBC had no effect on length of hospitalization. Duration of hospitalization was, 
however, considerably longer in these anemic patients than for average Finnish 
mothers (5.2 days versus 3.5 days). Most of the platelet (PLT) products were 
transfused to hematological patients (43%). Only 1% of surgical patients 
received PLTs. Most of the PLT-transfused patients were surgical (54%). PLT 
recipients undergoing surgery had higher in-hospital mortality rates (13.1%) 
than did PLT-transfused patients overall (9.5%). Severity of underlying condition 
as judged by the American Society of Anesthesiologists’ Physical Status (ASA) 
Classification in surgical patients had an effect on prevalence of blood 
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transfusions. For example, patients classified to ASA grade 3 or 4 received 
almost 70% of all transfused blood products. Severity of disease was used in our 
study to predict RBC need in hip-arthroplasty patients. 
Variability in blood-use practices suggests inappropriate blood use. Moreover, 
RBC transfusion in paired units is a questionable practice. FFP transfusions, not 
based on coagulation tests, suggest inappropriate use of plasma as well. In 
parturients, mild anemia treated with 1 to 2 units of RBCs does not shorten 
hospitalization time. This supports the current recommended thresholds for RBC 
transfusion. Improvement efforts concerning PLT-use practices may be directed 
to users of high doses of PLTs; to hematological patients, but also to digestive 
tract surgery and cardiac surgery patients who receive a large amount of 
transfused PLTs. Knowledge of severity of the underlying disease as affecting 
the transfusion requirement may facilitate optimization of blood use. 
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INTRODUCTION 
Blood transfusion has been an important part of medical treatment since World 
War II. Blood-component treatment can be lifesaving in many situations, but 
blood administration has physiological and immunological effects that can be 
harmful or can hamper later transfusions. Annually in Finland, approximately 
200 to 300 harmful reactions from blood transfusion are reported to the Finnish 
Red Cross Blood Service (FRC BS) (Adverse effects of blood transfusion 2010, 
2011). Some 20 to 40 of these are considered serious. 
The most common serious hazard of transfusion is the administration of a blood 
component intended for another patient (Adverse effects of blood transfusion 
2010, 2011). Transfusions can cause adverse effects (anaphylaxis, transfusion-
related lung injury: TRALI), and infections can be transmitted via blood (human 
immunodeficiency virus, hepatitis, prion diseases) (Schreiber et al., 1996; 
Sandler, Vassallo, 2001; Kleinman et al., 2004; Lefrère, Hewitt, 2009). 
Furthermore, duration of RBC storage is associated with an increase in adverse 
outcomes (Spinella et al., 2009; Pettilä et al., 2011). True transfusion reactions 
and infectious problems are, fortunately, rare. However, unnecessary blood 
transfusions expose patients needlessly to potential risks from transfusions. 
Blood collection and preparation are costly. In 2010, Finnish hospitals spent over 
45 million euros to purchase blood components from the FRC BS (The Blood 
Service in 2010, 2010). No information exists as to Finnish hospitals’ laboratory, 
personnel, supplies, and additional costs associated with blood transfusions, but 
studies from several countries suggest that, from a larger, societal perspective, 
blood component use costs are much higher and increasing (Cremieux et al., 
2000; Varney et al., 2003; Amin et al., 2004; Glenngård et al., 2005). All this 
justifies the conclusion that unnecessary blood transfusions produce redundant 
healthcare costs. 
Aging of the population strains the supply chain of blood components. One 
estimate is that in the United Kingdom within 20 years, use of blood products 
will increase by 20% compared to the supply (Currie et al., 2004). The number 
of eligible blood donors might become insufficient in the near future. 
Practically no information exists as to the current epidemiology of blood 
transfusions in Finland. Studies on blood use show, however, great variation 
between hospitals and countries (Sirchia et al., 1994; Kytölä et al., 1998; 
Capraro et al., 1998, 2000). Variation has been thought primarily to reflect 
differences in clinical transfusion practices. Up to several-fold differences in the 
percentage of transfused patients or in the number of transfused blood 
components indicate that blood use cannot always be optimal. Knowledge of 
current blood use indications does not coincide with clinical practice, or it just 
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might be scanty. Commonly accepted and applied guidelines or working 
methods might facilitate everyday clinical work and more importantly, improve 
patient care. 
To improve blood use practices, the need for current epidemiology is 
acknowledged. Most effectively, continuous follow-up of blood use would be 
accomplished by a healthcare integrated information system. It would offer the 
possibility for administrators and clinical personnel performing transfusions to 
monitor hospitals’ individual blood use and to compare practices between 
hospitals (i.e. benchmarking). Furthermore, it could provide a data foundation 
for interventions to change transfusion practices. 
For this study we developed a permanent national registry of blood component 
use utilizing electronic hospital information systems. We studied epidemiology of 
blood component use and Finnish blood use practices. Furthermore, in specific 
groups, particular issues related to transfusions were chosen and examined 
more close, like indications for blood transfusions, correlation between blood 
transfusions and length of hospital stay, and in-hospital mortality. The aim of 
the present study was to provide tools for transfusion practice improvement by 
providing information about blood use and by suggesting clinically useful 
measures for the advancement of blood-use practices. 
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REVIEW OF THE LITERATURE 
1. Epidemiology of blood component use 
Epidemiological information on blood component use is limited. Most information 
has concentrated on certain blood components, diagnoses, or surgical 
procedures, on particular areas or hospitals, and has restricted the data 
gathered by time limits, thus lacking follow-up on changing practices. 
Furthermore, data collection requiring manual manpower has proven laborious. 
Only a few studies extend these limits (Sirchia et al., 1994; Mathoulin-Pelissier 
et al., 2000; Titlestad et al., 2001, 2002; Wells et al., 2002; Snyder-Ramos et 
al., 2008; Kamper-Jørgensen et al., 2009). The Sanguis study compared blood 
component use practices in 43 teaching hospitals in 10 European countries for 
six commonly performed elective surgical procedures (Sirchia et al., 1994). 
Titlestad et al. (2001, 2002) used computerized registries to study transfused 
patients. RECEPT investigators searched transfusion-related variables based on 
a random sampling method to study 3,206 transfused patients in 175 hospitals 
across France, and Wells et al. (2002) conducted a study based on hospital 
blood-bank information in northern England for a population of 2.9 million 
(Mathoulin-Pelissier et al., 2000). Snyder-Ramos et al. (2008) studied 5,065 
randomly selected cardiac surgery patients in 70 centers among 16 countries in 
North and South America, Europe, the Middle East, and Asia. A Danish-Swedish 
group combined transfusion information in order to study population-based 
blood transfusion exposure (Kamper-Jørjensen et al., 2009). 
1.1. Clinical use of red blood cells 
According to several studies, roughly half of all RBC units are used for surgical 
indications and the other half for other medical indications (Friedman et al., 
1980, 1982; Cook and Epps, 1991; Ghali et al., 1994; Vamvakas and Taswell, 
1994; Chiavetta et al., 1996; Beguin et al., 1998; Stanworth et al., 2002; Wells 
et al., 2002; Wallis et al., 2006; Barr et al., 2010). RBC-transfused patients are 
generally elderly. About half of all RBC recipients are aged 65 years or more 
(Wells et al., 2002, 2009; Cobain et al., 2007; Barr et al., 2010; Borkent-Raven 
et al., 2010; Bosch et al., 2011). More women are transfused with RBCs than 
men, but men are transfused with more RBC units than are women, on average 
(Vamvakas and Taswell, 1994; Zimmermann et al., 1997, 1998; Wells et al., 
2002, 2009; Anderson et al., 2007; Cobain et al., 2007; Menis et al., 2009; Barr 
et al., 2010; Borkent-Raven et al., 2010; Madren et al., 2010; Bosch et al., 
2011). Most of the RBCs are transfused to patients with malignancies or 
gastrointestinal or cardiovascular diseases, or to trauma patients (Chiavetta et 
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al., 1996; Zimmermann et al., 1997, 1998; Mathoulin-Pelissier et al., 2000; Lim 
et al., 2004; Cobain et al., 2007; Wells et al., 2009; Barr et al., 2010; Borkent-
Raven et al., 2010; Madsen et al., 2010; Bosch et al., 2011). Major RBC 
recipients are patients with coronary heart disease as their recorded main 
diagnosis (Chiavetta et al., 1996; Titlestad et al., 2001; Anderson et al., 2007; 
Menis et al., 2009; Bosch et al., 2011). In the perioperative setting, RBCs are 
transfused most often to orthopedic and cardiac or vascular surgery patients 
(Chiavetta et al., 1996; Stanworth et al., 2002; Wells et al., 2002; Anderson et 
al., 2007). The majority of surgically treated RBC receivers undergo abdominal 
surgery, coronary artery bypass (CABG), or hip replacement. Study details of 
previous RBC use research are in the appendix. 
Cardiac surgery and red blood cell transfusion 
Cardiac surgery remains one of the major consumers of allogeneic blood 
(Society of Thoracic Surgeons Blood Conservation Guideline Task Force, 2011). 
Vascular surgery and use of cardiopulmonary bypass expose these patients to 
major bleeding, so CABG patients represent the single largest group of blood 
recipients (Surgenor et al., 1992). Goodnough et al. (1991) estimated that in 
the U.S. CABG patients comprise nearly 10% of annual RBC recipients. They 
found in their 18-institution study of 540 elective CABG patients that 68% of the 
patients received RBCs. Surgenor et al. (1992) reported at the same time that 
isolated CABG patients (including primary and re-do operations) received a 
mean 4.3 to 6.7 units of RBCs depending on type of procedure. RBC transfusion 
frequency (71-85%) also varied between operation types. Variation is evident in 
CABG patients’ RBC transfusion frequencies, ranging from 0 to 100% (Sirchia et 
al., 1994; Hasley et al., 1995; Stover et al., 1998, 2000; Snyder-Ramos et al., 
2008; Mehta et al., 2009). A study in Finnish hospitals found 87% (range 53-
99%) of first-time, elective CABG-operated patients receiving RBCs (Kytölä et 
al., 1998). Reported figures from Japan (74%) and the U.S. (34%) have been 
lower (Isomatsu et al., 2001; Covin et al., 2003). However, according to The 
Society of Thoracic Surgeons Blood Conservation Guideline Task Force (2007), 
more than half of all cardiac patients do not receive blood products; of blood 
units transfused, a minority (15-20%) of operated cardiac patients consume 
most: 80%. A restricted program of RBC use is possible, since of 441 
consecutive CABG patients of one surgeon, only 10% received RBCs (mean 
0.3±1.4 units) (Cosgrove et al., 1985). 
 
Abdominal aortic surgery patients and red blood cell transfusion 
Vascular surgical procedures are often accompanied by excessive bleeding. 
When Hallett et al. (1987) studied the effect of an autotransfusion device in 
elective abdominal aortic surgery, they found 96% of elective abdominal aortic 
surgery patients to require allogeneic blood (RBCs or whole blood). Use of 
autotransfusion reduced the percentage of allogenic transfusion recipients to 
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32%. Sirchia et al. (1994) found the frequency of transfused abdominal aorta 
aneurysmectomy patients to vary markedly among 43 hospitals (mean 53.7%, 
range 7-100%). When Long et al. (2010) studied retrospectively open 
abdominal aortic aneurysm repair patients and compared RBC transfusion 
practices between 1980 to 1982 and 2003 to 2006 in the Mayo Clinic, they 
found a statistically significant decrease in intraoperatively RBC-transfused 
patients in the latter observation period (99% vs. 46%). 
 
Hip’ and knee-replacement patients and red blood cell transfusion 
Orthopedic surgery is associated with major perioperative blood loss. Most 
orthopedic blood recipients studied are total hip- and knee-replacement 
patients. Surgenor et al. (1991) investigated 4,315 primary hip’ or knee-
replacement patients and found large variation in RBC requirements (hip: 54-
87% transfused; knee: 33-78% transfused). Hasley et al. (1995) studied 7,173 
patients undergoing hip’ or knee-replacement. They found 69% (range 36-95%; 
mean units 2.6, SD 1.4) of hip’ and 51% (9-97%; mean units 2.2, SD 0.9) of 
knee-replacement patients to receive RBCs. The percentage of RBC recipients 
among hip-replacement patients was lower (57%, range 0-100%, median of 
units 3, range 2-5) in the Sanguis study with 1,647 patients (Sirchia et al., 
1994). In Finland, Capraro (1998) found 92% (mean units 3.6, SD 2.3) of 
primary unilateral total hip’ and 84% (mean units 2.6, SD 2.0) of knee-
replacement patients to need allogeneic RBCs during 1992-1994. The 
percentage of allogeneic RBC recipients in these elective orthopedic procedures 
has ranged from 10 to 35% depending on autotransfusion regimen in three 
large studies from Europe and the U.S. (Bierbaum et al., 1999; Borghi et al., 
2000; Rosencher et al., 2003). 
Feagan’s group (2001) studied 2,032 consecutive patients undergoing hip-and 
knee replacements and the effect of autologous blood donation on their blood 
requirement. They found the percentage of allogeneic RBC receivers in primary 
hip replacement to be 30% (7% in the autologous blood-donation group) and in 
the primary knee replacement procedure 17% (7% in the autologous blood 
donation group). The mean number of allogeneic RBC units transfused were a 
respective 2.3 (1.7) and 2.3 (3.0). Utilizing patient-related indicators when 
ordering RBCs for total hip arthroplasty reduced the amount of crossmatched 
RBCs by 61% and the efficiency of blood-ordering practices rose (Nuttall et al., 
1996, 1998). 
 
Femoral-neck fracture patients and red blood cell transfusion 
Fracture of the femoral neck is associated with bleeding and need for 
transfusions (Friedman et al., 1980; Wells et al., 2002). Swain et al. (2000) 
studied their operated and non-operated femoral-neck fracture patients and 
found 53% to have been transfused with a mean of 2.6 units of RBCs. This 
percentage of transfused and operated hip-fracture patients has shown a 
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variability between 24 and 61% in three studies from the U.S. and Canada 
(Goodnough et al., 1993; Poses et al., 1998; Hutton et al., 2005). Johnston et 
al. (2006) reported an allogeneic blood transfusion rate of 30% in their operated 
hip-fracture patients with no association between transfusion and mortality rate. 
The surgical technique chosen has been shown to influence RBC requirements in 
hip-fracture patients, with replacement arthroplasty patients needing more 
blood transfusions than did patients treated with internal fixation (Parker and 
Gurusamy, 2006; Parker and Handoll, 2006). Hutton et al. (2005) showed 
variability in mean nadir Hb counts after adjustment for age and gender 
following hip-fracture repair. Mean Hb counts ranged between Canadian 
hospitals from 71.2±2.9 g/l to 82.8±1.7 g/l (mean 77.6±11.6 g/l). 
 
Gastrointestinal bleeding and red blood cell transfusion 
Hematemesis and melena are the major signs of gastrointestinal bleeding most 
often caused by ulcers, varices, or gastrointestinal tumors. Coagulopathy caused 
by liver dysfunction occurs commonly in these patients and is associated with 
massive hemorrhage. The A/S/G/E Bleeding Survey, conducted in 1978 and 
1979 (Gilbert, 1990), was a prospective study comprising 2,225 patients with 
upper gastrointestinal bleeding. They found 26% of patients each requiring more 
than 5 units of RBCs (median 3.6 units). A study of 4,664 gastric and duodenal 
ulcer patients found an RBC transfusion frequency of 50% (range 11-76% 
between hospitals) (Hasley et al., 1995). One 7-year retrospective study of 
patients with gastrointestinal bleeding showed patients with portal hypertension 
(90% were transfused) and with gastric (69%) and duodenal ulcers (53% 
required RBC transfusion) to require most of the transfused RBC units (Garrido 
et al., 2006). Advances in endoscopic methods and novel pharmacologic 
approaches have reduced the need for transfusions in patients with upper 
gastrointestinal bleeding. Hospitalization of these patients has shown a 
decrease. Re-bleeding for variceal patients decreased from 10% in 1991 to 6% 
in 2000 and for non-variceal patients from 8% in 1997 to 6% in 2000 (Lee et 
al., 2005). 
 
Colorectal resection for cancer and red blood cell transfusion 
High rates of perioperative blood transfusion ranging from 20% to 70% have 
been reported for patients undergoing colorectal resection for cancer (Francis et 
al., 1987; Weiden et al., 1987; Tang et al., 1993; Donohue et al., 1995; 
Chiarugi et al., 1996; Edna and Bjerkeset, 1998; Vamvakas and Carven, 1998; 
Benoists et al., 2001; Skånberg et al., 2007). In one 14,052 colorectal-surgery 
data-set, only 19% of patients received transfusions (allogeneic or autologous 
RBCs, FFP, or PLTs) (Nilsson et al., 2002). A decreased transfusion requirement 
is associated with greater operation volume/surgeon per year and also with a 
hospital’s lower annual patient volume. Rate of RBC transfusion in colorectal 
surgery was almost the same, 20%, in a study by Kim et al. (2007). Choosing 
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laparoscopy-assisted surgery instead of conventional open surgery reduces the 
percentage of patients transfused (Ohtani et al., 2011). 
 
Trauma patients and red blood cell transfusion 
Trauma is a major cause for bleeding, and about 10 to 15% of all transfused 
RBCs go to trauma patients (Friedman et al., 1980). Wudel et al. (1991) studied 
massively transfused blunt-trauma patients in the U.S.; a total of 6,142 patients 
were admitted for trauma in their level I-trauma center, when patients with 
penetrating trauma or burns were excluded. They found 92 of these patients 
had received transfusion of 20 or more RBC units, totaling 3,004 units of RBCs. 
Como et al. (2004) reported that of 5,645 acute-trauma patients, 8% received 
RBCs. Of these 5,645 injured individuals, 147 (3%) received more than 10 units, 
and they were transfused with 71% of all RBCs given. Mc Roberts et al. (2007) 
confirmed the finding of a minority of injured patients receiving the greatest 
volume of blood products. A post hoc analysis of the CRIT study in the U.S. 
showed that 55% of trauma patients in intensive care units received RBCs 
(Shapiro et al., 2003). Of 120 trauma patients expected to remain in the 
surgical intensive care unit (ICU) for longer than 48 hours, 87% (104) received 
RBCs (Beale et al., 2006). In a nationwide benchmarking study from the U.S., 
15% of trauma patients requiring ICU care received RBCs (Lilly et al., 2011). 
 
Intensive care patients and red blood cell transfusion 
In intensive care patients, anemia is very common. Epidemiological studies in 
the 1990s found 30 to 85% of ICU patients receiving RBCs (Corwin et al., 1995; 
Littenberg et al., 1995; Borum et al., 2000), and during this same time-period, 
Groeger et al. (1993) found 27% of patients in surgical ICUs and 16% in 
medical ICUs as being transfused with RBCs. RBC transfusion practices seem to 
have changed little over the decade. Vincent et al. (2002) studied 3,534 patients 
admitted to 146 western European ICUs in the ABC trial. Transfusion rate during 
their ICU stay was 37%, and the mean number of transfused RBC units was 4.8 
(SD 5.2). Mean age of the patients was 61 (SD 17), with the majority being 
males (62%). Emergency surgery patients were transfused with RBCs most 
often (57%), followed by trauma patients (48%), elective surgery patients 
(42%), and other medical patients (32%). 
Corwin et al. (1995), in a prospective, multi-center, observational CRIT study of 
248 ICUs in the U.S. with 4,892 patients, found that 44% of critically ill patients 
received RBCs (mean 4.6, SD 4.9 units). In these large, prospective studies 
from Europe and the U.S., mean pretransfusion Hb was 84 (SD 13 g/l) and 86g/l 
(SD 17 g/l), respectively (Vincent et al., 2002; Corwin et al., 2004). Rao et al. 
(2002) studied transfusion frequencies in nine ICUs in the U.K., where 53% of 
ICU patients received RBCs. Hemorrhage patients received on average 6.75 
units of RBCs and anemia patients 4.25 units. Over half (91 of 176) of one 
teaching hospital’s ICU patients received RBCs (Chohan et al., 2003). 
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These findings differ widely from those of an Australian study in a university-
associated tertiary hospital in which only 23% of intensive care patients were 
transfused (Farrar et al., 2004), and from the ATIC study group’s in 10 ICUs in 
Scotland where 40% of ICU admissions were associated with RBC transfusion 
(Walsh et. al., 2004). A recent benchmarking study including 243,533 adult ICU 
admissions in the U.S. reported 19% of patients as receiving RBCs (Lilly et al., 
2011). 
 
Obstetric and gynecological patients and red blood cell transfusion 
Obstetric hemorrhage remains a major cause for maternal mortality (Khan et 
al., 2006; Knight et al., 2009). Unfortunately, most deaths involve substandard 
care, so there may be room for improvement of transfusion procedures (Bonnet 
et al., 2011). Otherwise obstetric and other gynecological patients require blood 
transfusions relatively infrequently. This patient population accounts for 2 to 6% 
of all RBC use, with variation between studies (Chiavetta et al., 1996; Stanworth 
et al., 2002; Wells et al., 2002). 
Cesarean section and hysterectomy are the two surgical procedures performed 
most often. Transfusions are necessary in 0.3 to 3% of vaginal and in 0.7 to 
12% of cesarean deliveries (Hill and Lavin, 1983; Andres et al., 1990; Klapholz, 
1990; Dickason and Dinsmoor, 1992; Goudan et al., 2011). A number of 
hysterectomy patients are also transfused, and as many as 17 to 75% of these 
patients reportedly receive RBCs (Mintz and Sullivan, 1985; Palmer et al., 
1986). A more recent study by Kohli et al. (2000) reported a 3.4% incidence of 
blood transfusion among elective hysterectomy patients and noticed that routine 
Hb monitoring after surgery in asymptomatic women did not improve outcome. 
Bleeding complications necessitating blood transfusion perioperatively were in 
one study more common in vaginal hysterectomies than in abdominal 
procedures for benign diseases in Finland (Mäkinen et al., 2001), but this finding 
disagrees with Turkish researchers’ retrospective findings that vaginal 
hysterectomy patients less frequently received blood (Doganay et al., 2011). 
The incidence of transfusion was low in both studies (vaginal hysterectomy: 3% 
vs. 2%, abdominal hysterectomy: 2% vs. almost 3%). 
 
Dosing of red blood cells 
Several studies from Denmark, the U.S., Australia, Austria, and the Netherlands 
show that RBC units are transfused most often in paired doses (Titlestad et al., 
2001; Shapiro et al., 2003; Grey et al., 2006; Gombotz et al., 2007; Borkent-
Raven et al., 2010). Routine paired dosing of RBCs can be seen in various 
specialities (Grey et al., 2006). 
1.2. Clinical use of fresh frozen plasma 
Two-thirds of FFP units are transfused to surgical patients (Cook and Epps, 
1991; Iorio et al., 2008). Most FFP recipients are male, and the majority of FFP 
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units go to male patients (Vamvakas and Taswell, 1994; Zimmermann et al., 
1997, 1998; Cobain et al., 2007; Iorio et al., 2008; Mirzamani et al., 2009; 
Wells et al., 2009; Borkent-Raven et al., 2010; Bosch et al., 2011). The majority 
of FFP recipients are elderly, with 40 to 50% of FFP units transfused to patients 
over 65 (Zimmermann et al., 1998; Cobain et al., 2007; Iorio et al., 2008; 
Mirzamani et al., 2009; Wells et al., 2009; Borkent-Raven et al., 2010; 
Stanworth et al., 2011). FFP recipients are, however, younger on average than 
RBC recipients (Cook and Epps, 1991; Tynell et al., 2001; Cobain et al., 2007; 
Borkent-Raven et al., 2010). The majority of FFP recipients have a 
gastrointestinal or circulatory system disease, malignancy, or trauma 
(Zimmermann et al., 1997, 1998; Mathoulin-Pelissier et al., 2000; Lim et al., 
2004; Cobain et al., 2007; Mirzamani et al., 2009; Wells et al., 2009; Borkent-
Raven et al., 2010; Bosch et al., 2011). The most frequent diagnosis associated 
with FFP transfusion is coronary artery disease (Titlestad et al., 2001; Bosch et 
al., 2011). Study details of previous FFP use research are shown in the 
appendix. 
Digestive system diseases and FFP transfusion 
Patients with gastrointestinal disease require FFP transfusion for the same 
indications as with RBCs (ulcers and varices), and the most common 
abnormality seen with gastrointestinal bleeding is the coagulopathy of liver 
disease. Reports are fewer on the FFP requirement in gastrointestinal patients 
than on RBC transfusions. However, a survey from the USA on gastrointestinal 
bleeding caused by varices found 45% of these patients to require FFP 
transfusions during their first bleeding episode (median 3 units) (Sorbi et al., 
2003). The FFP transfusion rate was higher during re-bleeding (51%). In 2007, 
24% of all transfused FFP units in Catalonian hospitals were for patients with 
gastrointestinal disease (Bocsh et al., 2011). 
 
Cardiovascular disease and FFP transfusion 
Up to 50% of FFP units are transfused to patients with cardiovascular disease 
(Zimmermann et al., 1997; Cobain et al., 2007; Wells et al., 2009; Borkent-
Raven et al., 2010; Bosch et al., 2011). The Sanguis study group found 39% 
(range 0-100%) of European CABG patients being transfused with FFP at a 
median of four units each (range 1-10) (Sirchia et al., 1994). A later study from 
the USA, including 18 institutions, found 32% (range 0-97%) of first-time, 
elective CABG patients receiving FFP (Goodnough et al., 1991). Moreover, a 
study of nine centers in Finland showed that 25% (range 5-49%; mean number 
of transfused units 2.8, SD 1.9) of these patients received FFP transfusions 
(Kytölä et al., 1998). Stover et al. (1998) also found a high variability in FFP 
transfusion practices, 0 to 36% of CABG patients being transfused with FFP. 
However, the percentage of FFP-transfused patients in the USA reported by 
Covin et al. (2003) was lower, 9% (range 0-10%). Snyder-Ramos et al. (2008) 
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also found variability in FFP transfusion practices in patients undergoing CABG 
among 70 centers in 16 countries in North and South America, Europe, the 
Middle East, and Asia. FFP transfusion frequencies ranged from 0 to 98% 
intraoperatively, and from 3 to 95% postoperatively. 
 
Intensive care patients and FFP transfusion 
Patients with major bleeding often require ICU care. FFP has been transfused to 
23% of patients admitted to an ICU, and 32% of FFP-transfused patients have 
been in an ICU (Rao et al., 2002; Stanworth et al., 2011). Lilly et al. in 2011, 
reported, however, only 5% of ICU patients in the USA as receiving FFP in a 
study including 243,533 adult patient admissions in 271 ICUs located in 188 
hospitals. Dara et al. (2005) found 38% of ICU patients with a prolonged 
international normalized ratio (INR; INR≥1.5) without active bleeding as 
receiving FFP. The majority of FFP is transfused for prophylactic reasons (Dara 
et al., 2005; Stanworth et al., 2011). 
 
Dosing of FFP 
In Denmark and the Netherlands, FFP units are administered in pairs, as are 
RBCs (Titlestad et al., 2001; Borkent-Raven et al. 2010). No explanation for this 
practice, except as a custom of medical personnel, has emerged (Titlestad et al., 
2001). 
1.3. Clinical use of platelets 
Over half of all PLT recipients in the USA are surgical patients (Cook and Epps, 
1991). About two-thirds of PLT-transfused patients are male, and they receive 
roughly 60% of transfused PLTs (Vamvakas and Taswell, 1994; Zimmermann et 
al., 1997, 1998; Cobain et al., 2007; Wells et al., 2009; Borkent-Raven et al., 
2010; Bosch et al., 2011). PLT-transfused patients are on average younger than 
are RBC and FFP recipients (Cobain et al., 2007; Greeno et al., 2007; Borkent-
Raven et al., 2010). Most PLTs are transfused to patients with a malignancy 
(Zimmermann et al., 1997; Mathoulin-Pelissier et al., 2000; Titlestad et al., 
2001; Lim et al., 2004; Cobain et al., 2007; Greeno et al., 2007; Quareshi et 
al., 2007; Wells et al., 2009; Borkent-Raven et al., 2010; Bosch et al., 2011). 
Study details of earlier PLT use research are in as appendix. 
Hematological patients and PLT transfusion 
Prophylactic PLT transfusions are often given to reduce risk for hemorrhage in 
patients undergoing chemotherapy for cancer. Most PLT-transfused cancer 
patients have a hematological malignancy, and patients with acute leukemia and 
bone marrow transplants receive most of the PLT transfusions (Bayer et al., 
1992; Zimmermann et al., 1997; Meehan et al., 2000; Titlestad et al., 2001). 
Cameron et al. (2007) reported at their referral hospital that 67% of PLT 
transfusions went to hematological patients, most (78%) being for prophylaxis. 
 21 
Cardiac surgery and PLT transfusion 
Cardiac surgery patients often receive PLTs perioperatively. Use of 
cardiopulmonary bypass has an effect on the number and function of PLTs. Of 
the Goodnoughs et al. (1991) first-time, elective CABG-operated patients in the 
USA, 22% (range 0-80%) received PLTs, whereas Kytölä et al. (1998) found a 
rate in Finland of only 9% (range 2-22%; mean of transfused units 8.3; SD 
3.6). Stover et al. (1998) found that the percentage of PLT-transfused CABG 
patients in the USA differed between hospitals, ranging between 0 and 36%. In 
a more recent study from the USA, Covin et al. (2003) found the percentage to 
be 10% (range 4.8-18.4%). Snyder-Ramos et al. (2008) found their percentage 
of CABG PLT-transfused patients to be 17% (mean of transfused units 6.9) in an 
international comparative study. 
 
Intensive care patients and PLT transfusion 
Rao et al. (2002) studied critically ill patients in the U.K. and found 16% of ICU 
patients to receive PLT transfusions. Most patients (44%) received PLTs with a 
transfusion trigger of a PLT count between 50 and 100x109/L. Arnold et al. 
(2006) found 23% of adult ICU patients who were expected to stay in an ICU for 
at least 72 hours (excluding trauma-, orthopedic- and cardiac-surgery patients) 
as receiving PLT transfusions. PLT transfusion triggers (median) for prophylactic 
PLT transfusion were 41x109/L and for therapeutic purposes higher, 51x109/L. 
Lilly et al. (2011) found in their benchmarking study from the USA that only 3% 
of adult ICU patients received PLTs. 
1.4. Use of blood components by diagnosis-related 
groups 
One way of approaching blood-component use is to analyze the cost of 
transfusion care. Originally developed for reimbursement and for a description of 
hospital activity, diagnosis-related groups (DRG) have been utilized for study of 
transfused patients. The DRG classification is based on the idea that similar 
patients require similar resources during any one treatment episode. Cook and 
Epps (1991) found that 74% of transfused patients, 74% of transfusion 
episodes, and 76% of transfused blood components (RBC, FFP, and PLT) were 
transfused to patients in 5 of the 18 major DRGs: 1. cardiovascular (24% of RBC 
units and 34% of FFP units), 2. neoplasm (26% of PLT units), 3. digestive, 4. 
injury/poisoning, and 5. musculoskeletal diagnoses. Jefferies LC et al. (2001) 
studied in 1995 the transfusion costs in 60 hospitals and found the DRGs: 1. 
bone marrow transplantation, 2. liver transplantation and 3. acute leukemia 
(without major operating room procedure: age over 17 years), to induce the 
highest blood costs. 
In 1998 Syrjälä et al. (2001) found in one Finnish university-hospital setting the 
highest blood component costs in DRG groups: in acute leukemia (without major 
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operating room procedure: age>17 years), in bone marrow transplantation, and 
in lymphoma or non-acute leukemia without complications. A recent study from 
Australia found that patients receiving most of the transfused RBCs either had a 
tracheostomy or were patients ventilated for over 95 hours, patients with RBC 
disorder without catastrophic or severe comorbidities, and patients with 
lymphoma and non-acute leukemia (Allden et al., 2011). Surgenor et al. (1989, 
1991, 1992, 1998) and Vamvakas (1998) also utilized DRG groups to study 
transfusion practices. 
1.5. Variation in blood-use practices 
Variation in blood-component usage has been well documented (Surgenor et al., 
1989; Goodnough et al., 1991; Baele et al., 1994; Sirchia et al., 1994; Hasley 
et al., 1995; Audet et al., 1998; Capraro et al., 1998; Kytölä et al., 1998; 
Stover et al., 1998; Surgenor et al., 1998; Hebert et al., 1999; Feagan et al., 
2001; Vincent et al., 2002; Rosencher et al., 2003; Hutton et al., 2005; 
Gombozt et al., 2007; Snyder-Ramos et al., 2008). Variation has occurred 
within specific disease categories and surgical procedures, within clinical settings 
and between institutions. The Sanguis group study of 1994 found the 
percentage of transfused elective surgery patients in 43 European countries to 
range among hospitals from 0 to 100%. Hebert et al. (1999) found the mean 
pretransfusion Hb to range in Canadian ICU patients from 87 g/l to 95 g/l, and 
Hutton et al. (2005) observed nadir Hb to range from 67 g/l to 85 g/l in various 
surgical and critical care patient groups. Transfusion rates depend on patient 
population, on differences in perioperative blood loss, and on the treating 
physicians. Many authors have concluded that variation in blood use practices 
suggests inappropriate use of blood components. 
2. Optimal use of blood components 
Few randomized, controlled trials concern the clinical use of blood components, 
and the majority of guidelines are based on clinical experience and professional 
consensus (Table 1). 
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Table 1. Guidelines for use of blood components. 
 
2.1. Guidelines for use of red blood cells 
In the past, clinicians have used the 100/30 transfusion rule as a transfusion 
trigger to keep patients’ Hb concentrations above 100 g/l and hematocrits (Hct) 
above 30%. Over the years, the scientific foundation for this trigger to transfuse 
RBCs has been challenged. 
RBCs are transfused depending on patient’s clinical condition, ability to tolerate 
anemia, and bleeding status. Recommendations exist for clinicians regarding Hb 
thresholds to trigger RBC transfusion, but no optimal strategy has been defined 
for treatment of a particular single patient (Crosby et al., 1997; Council NHAMR, 
2001; Murphy et al., 2001; American Society of Anesthesiologists Task Force, 
2006). For most non-bleeding patients, RBC transfusion is probably unnecessary 
until the Hb value drops below 70 g/l, with the exception of patients with severe 
coronary disease (Hebert et al., 1999, 2001; Carless et al., 2010). These 
patients probably require higher Hb levels to ensure adequate oxygen delivery 
to the cardiac muscle. Furthermore, patients with acute blood loss of 30 to 40% 
of blood volume most probably need RBC transfusions (Murphy et al., 2001). 
Moreover, massively bleeding patients benefit from a higher Hb target due to 
the acute nature of the bleeding, and because Hct as high as 35% may be 
required to sustain hemostasis (Blajchman et al., 1994; Hardy et al., 2004, 
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2005). The possibility to monitor the patient (blood pressure, heart rate, 
electrocardiography, cardiac index, mixed venous oxygen saturation) helps to 
assess the adequacy of perfusion and oxygenation of vital organs (American 
Society of Anesthesiologists Task Force, 2006). 
Randomized, controlled data to support these guidelines come from a small 
number of studies including mainly adult patients. Current evidence on clinical 
outcome on the subject of transfusion thresholds appears in a Cochrane 
metanalysis by Carless et al. (2010). They found altogether 17 randomized, 
controlled studies comparing clinical outcomes in patients randomized to 
restrictive or liberal transfusion thresholds over a time period exceeding 40 
years (Fisher and Topley, 1956; Blair et al, 1986: Fortune et al., 1987; Johnson 
et al., 1992; Hebert et al., 1995; Bush et al., 1997; Carson et al., 1998; Bracey 
et al., 1999; Hebert et al., 1999; Lotke et al, 1999; Grover et al., 2006; Lacroix 
et al., 2007; Colomo et al., 2008; Webert et al., 2008; Foss et al., 2009; Zygun 
et al., 2009; So-Osman et al., 2010). This metanalysis found that published 
evidence suggests no effect of conservative transfusion triggers on mortality, on 
rates of cardiac events, morbidity, or length of hospitalization. Especially if 
safety of the blood supply is in doubt, minimizing transfusions can be favorable. 
An even more recent randomized study enrolling hip-fracture surgery patients 
concluded that a liberal transfusion strategy reduced neither mortality nor 
patients’ ability to walk independently on the 60th-day control visit (Carson et 
al., 2011). This agrees with earlier findings (Carson et al., 1998). 
Children’s optimal threshold for RBC transfusion has been evaluated in 
randomized studies. A Canadian research team studied stable, critically ill 
children treated in an ICU (Lacroix et al., 2007). They assigned 320 patients to 
an Hb trigger group at 70 g/l, and 317 patients to a group at 95 g/l. The 
restrictive transfusion strategy was as safe as a liberal one. A metanalysis for 
extremely low birth weight infants (under 1,500 g) found no statistically 
significant differences in serious morbidity or death between babies in restrictive 
and liberal transfusion threshold groups (Kirpalani et al., 2006; Chen et al., 
2009; Whyte et al., 2009; Nopoulos et al., 2011; Whyte and Kirpalani, 2011). 
Infants’ respiratory status (intubated or not intubated) and age influenced the 
targeted transfusion threshold values in these very small babies. 
2.2. Guidelines for use of fresh frozen plasma 
FFP transfusion is indicated in patients with a single coagulation factor deficiency 
when no virus-safe fractionated product is available, and for blood loss in 
patients with multiple coagulation factor deficiencies or disseminated 
intravascular coagulation (Crosby et. al., 1997; Council NHAMR, 2001; Agence 
Francaise de Securite des Produits de Sante, 2002; O’Shaugnessy et al., 2004). 
Furthermore, FFP is indicated in reversal of the warfarin effect in bleeding 
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patients, plasma exchange in thrombotic thrombocytopenic purpura (TTP), and 
prevention of bleeding in patients with liver diseases and prolonged protrombin 
time. Recent randomized evidence emphasizes the therapeutic use of FFP and 
use of coagulation tests to guide decision-making (O’Shaugnessy et al., 2004; 
Stanworth et al., 2004). Contraindications for FFP use are treatment for 
hypovolemia, for plasma exchange (except for TTP), for reversal of prolonged 
INR in the absence of bleeding, and when prothrombin time (PT), INR, and 
activated partial thromboplastin time (aPTT) are normal (O’Shaugnessy et al., 
2004; American Society of Anesthesiologists, 2006). Coagulation parameter 
thresholds triggering FFP transfusion in case of bleeding are presence of a PT 
greater than 1.5 times normal or INR greater than 2.0, an aPTT greater than 1.5 
to 2 times normal, or a fibrinogen level under 100 mg/dL (Task Force of College 
of American Pathologists, 1994; Crosby et. al., 1997; Council NHAMR, 2001; 
Agence Francaise de Securite des Produits de Sante, 2002; O’Shaugnessy et al., 
2004; American Society of Anesthesiologist, 2006). FFP dosage depends on the 
FFP product, clinical situation, and on coagulation monitoring availability. In 
Finland a starting dose of 10 to 15 ml/kg is the recommendation of the FRC BS, 
the supplier (Mäki ed., 2004). 
In support of currently recommended practice guidelines, randomized, 
controlled-study evidence on the effectiveness of FFP is limited (Murad et al, 
2010; Roback et al., 2010). Most randomized trials have been underpowered or 
lacked blinding. Furthermore, in the absence of randomized, controlled data on 
FFP transfusion-triggering laboratory values, clinical use of FFP becomes 
challenging. However, some randomized evidence exists. Rock et al., (1991) 
compared plasma exchange with plasma infusion in 102 TTP patients. They 
found improved rates of response and survival in their plasma-exchange group. 
The Northern Neonatal Nursing Initiative Trial Group compared FFP with volume 
expanders in preventing intraventricular hemorrhage in 518 neonates (The NNNI 
Trial Group, 1996). They found no effect from prophylactic use of FFP. Leese et 
al., (1987) studied 198 adult patients with acute pancreatitis, randomizing 
patients to receive either FFP or a colloid solution. No differences emerged 
between groups as to clinical or laboratory outcomes. More data are clearly 
needed (Wood et al., 2009). 
2.3. Guidelines for use of platelets 
Recent guidelines recommend prophylactic PLT transfusion for stable patients 
with cancer or a blood disorder when the patient’s PLT count falls below 
10x109/L (Ancliff and Marchin, 1998; Council NHAMR, 2001: Schiffer et al., 
2001; British Committee for Standards in Haematology, 2003; Stanworth et al., 
2004). Patients are recommended to be monitored carefully for signs and 
symptoms of increased risk for bleeding (including elevated body temperature, 
rapid decrease in PLT count, and sepsis) and the transfusion threshold requires 
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raising if appropriate. An ongoing international study evaluates the concept of 
prophylactic PLT use (Stanworth et al., 2010). In surgical patients, the threshold 
for prophylactic PLT transfusion is higher than in conservatively treated patients. 
For commonly practiced invasive procedures, a PLT count of 50 x109/L is 
adequate, with higher thresholds recommended for patients undergoing 
neurosurgery or ophthalmic surgery (100 x109/L), and for those having epidural 
anesthesia (80 x109/L) (Council NHAMR, 2001; Samama et al., 2006). Nordic 
guidelines for neuraxial blocks take into account the potential benefit of the 
block (Breivik et al., 2010). The PLT transfusion threshold recommended 
decreases when the benefit of block treatment improves. Prophylactic PLT 
transfusion is not recommended for patients on PLT inhibitor therapy. 
Furthermore, surgery-related guidelines emphasize documenting any PLT deficit 
with test results (British Committee for Standards in Haematology, 2003; 
American Society of Anesthesiologists Task Force, 2006; Samama et al., 2006). 
PLT dosage relates to each individual clinical situation. With acute massive 
bleeding, the suggested dose is 1 unit per 10 kg of body weight (Mäki ed., 
2004). 
Stanworth et al. (2004) reviewed randomized, controlled studies involving 
prophylactic PLT transfusions after chemotherapy and stem cell transplantation 
in patients with hematological malignancies. These included eight published 
trials (Roy et al., 1973; Higby et al., 1974; Solomon et al., 1978; Murphy et al., 
1982; Sintnicolaas et al., 1982; Heckman et al., 1997; Rebulla et al., 1997; 
Klumpp et al., 1999; Zumberg et al., 2002). Four of these studies took place 20 
to 30 years ago under conditions differing from those for current treatment. 
Metanalysis found no evidence to change current practice regarding 
recommendation of a prophylactic threshold of 10x109/L. Later, Diedrich et al. 
(2005) compared 166 allogeneic hematopoietic progenitor cell transplant 
recipients randomly assigned to receive PLTs with a transfusion trigger of less 
than 10x109/L or less than 30x109/L. They concluded that both thresholds were 
safe. For prophylaxis, the number of transfused PLTs has had no effect on 
incidence of bleeding in hematological patients (Slichter et al., 2010); they 
compared 1,272 patients receiving either low-, medium-, or high-dose PLTs per 
square meter of body-surface area. 
Most of the recommendations in the perioperative setting are based solely on 
expert opinion. Two small (60 and 28 patients), randomized studies on 
cardiopulmonary bypass patients showed that prophylactic PLT transfusions are 
ineffective. Studies suggest that PLTs are reserved for patients bleeding after 
cardiopulmonary bypass, when surgical causes for bleeding have been excluded 
(Harding et al., 1975; Simon al., 1984). 
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3. Use of electronic information in hospital 
databanks 
3.1. Finnish Hospital Discharge Register (FHDR) 
In Finland, information on hospital visits has been collected in the FHDR since 
1967 (Gissler and Haukka, 2004). From the mid 1980’s, hospitals have been 
sending this information in electronic form. Later, from the early 90’s, other 
databases and programs for different hospital functions (for example, electronic 
blood bank systems) have become common and more uniform, and the trend 
towards replacing all printed patient charts by computerized medical registers is 
nationwide (Koskimies, 1999). Information on FHDR was designed to serve 
healthcare planning purposes. Such data have been widely useful for research, 
but also for comparison of hospital practice and care improvement (for example 
in productivity of hospitals, in care for the elderly, in dental care) (Gissler and 
Haukka, 2004; Hospital benchmarking, 2005; Helin-Salmivaara et al., 2006; 
Winell et al., 2006). The quality of FHDR data has been good (Keskimäki and 
Aro, 1991; Kantonen et al., 1997; Pajunen et al., 2005; Mattila et al., 2008). 
3.2. Electronic information and transfusion 
research 
Electronic data have been sporadically used to study transfusion practices 
(Syrjälä et al., 2001; Titlestad et al, 2002; McClelland, 2007; Grey et al., 2006; 
Borkent-Raven et al., 2010). Information from electronic databanks designed for 
various purposes was combined in these studies and served for research. 
Transfusion-related electronic data have been gathered on a larger scale in 
Scandinavia. The Danish Transfusion Database was founded in 1997 to study 
Danish blood-component use practices (Dansk Transfusionsdatabase, home 
page on the Internet). The Danish database includes transfusion-related 
information on patient diagnosis, treatment, blood transfusions, and 
clinical/chemical parameters. Existing electronic registers and information 
systems gather this regularly updated transfusion data, and reporting has been 
mandatory for all Danish hospitals since 2006. Analysis of these data are 
published and accessible on the Danish Healthcare Services health portal on the 
Internet. 
The largest database including transfusion-related data in electronic form is the 
SCANDAT database. It was designed to study cancer incidence in blood donors 
and transfusion recipients and to investigate the possibility that cancer can be 
transmitted via blood transfusion (Edgren et al., 2006). The database comprises 
over 10 million blood donations and transfusions in Sweden and Denmark 
between 1968 and 2002 (SCANDAT, home page on the Internet). The blood 
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donation and transfusion data gathered from hospital blood bank databases was 
linked with the cause of death, hospital inpatient, and birth and cancer registers 
from both countries. Plans are to update it. 
4. Trends in blood component use 
4.1. Red blood cell usage 
The FRC BSs´yearly sales figures show a decreasing trend in RBC use in Finland 
(Figure 1, provided by Tom Krusius, medical director, FRC BS). Finland is one of 
the European countries in which RBCs are used quite liberally (Figure 2) (Council 
of Europe, 2001-2008). 
Figure 1. Red blood cell and whole blood units provided by the Finnish Red Cross 
Transfusion Service to Finnish hospitals, 1984-2011. 
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Figure 2. Red blood cell use per 1,000 population in European countries 2001-2008 
provided by the Council of Europe. 
 
4.4. Fresh frozen plasma usage 
Although indications for administration of FFP have tightened over the years, 
plasma transfusions are given more and more often (Figure 3, FRC BS sales 
figures provided by Tom Krusius, medical director, FRC BS; O’Shaugnessy et al., 
2004). Differing from the liberal usage of RBCs in Finland, Finnish FFP use 
seems to rank at the average international level (Figure 4) (Council of Europe, 
2001-2008). The Finnish FFP/RBC use ratio per 1,000 population is one of the 
lowest internationally (Figure 5) (Council of Europe, 2001-2008). In the USA the 
rising trend for FFP use resembles Finnish figures (Sullivan et al., 2007; National 
Blood Collection and Utilization Survey Report, 2009; Figure 3). The significant 
rise in FFP use seen in FRC BS sales figures is in part explained by the change in 
fresh frozen plasma product (Figure 3). The FFP product used previously 
comprised on average more coagulation factors per ml, and the size of the 
product was larger than was Octaplas®. 
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Figure 3. Fresh frozen plasma units provided in 1984-2011 by the Finnish Red Cross 
Transfusion Service and Octapharma to Finnish hospitals. 
 
Figure 4. Fresh frozen plasma use per 1,000 population in European countries 2001-
2008 provided by the Council of Europe. 
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Figure 5. Fresh frozen plasma use per red blood cell use per 1,000 population in 
European countries 2001-2008 provided by the Council of Europe. 
 
4.4. Platelet usage 
The FRC BSs overall PLT sales trend seems to be toward an increase (Figure 6, 
FRC BS sales figures provided by Tom Krusius, medical director, FRC BS). The 
recent PLT use trend in Europe seems to be more stable than trends for other 
blood products (Figure 7) (Council of Europe, 2001-2005). In the USA, PLT use 
is increasing, in agreement with FRC BS sales figures (Sullivan et al., 2007; 
National Blood Collection and Utilization Survey Report, 2009; Figure 6). 
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Figure 6. Platelet product use in Finnish hospitals 1984-2011. Each product equals 4 
units. 
 
Figure 7. Platelet use per 1000 inhabitants in European countries in 2001-2005 
provided by the Council of Europe. 
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4.4. Future trends in blood component use and 
costs 
 
The population structure in most Western countries is shifting from younger to 
older age groups. In Finland, the proportion of individuals aged over 65 is 
predicted to increase from 17% to 29% between 2009 and 2060 (Suomen 
virallinen tilasto, 2009). Aging leads to increased risk for disease and need for 
transfusions (Wells et al., 2002, 2009; Cobain et al., 2007; Akif et al., 2010; 
Barr et al., 2010; Borkent-Raven et al., 2010; Bosch et al., 2011). The eligible 
donor group will be smaller in an aging population, and concern has arisen as to 
the sufficiency of the future blood supply (Currie et al., 2003; Borkent-Raven et 
al., 2010; Katalinic et al., 2010; Greinacher et al., 2011). Variables such as 
optimizing blood component use may counterbalance the predicted need for 
transfusions (Borkent-Raven et al., 2010). 
Increased demand for blood components raises the cost of transfusion therapy. 
In addition, improving product safety (screening for infectious agents, 
leukoreduction, solvent/detergent treatment) or other increasing annual 
expenses involving collection, preparation and distribution raise the cost for 
blood products paid by the hospitals (Table 3). Blood product processing by the 
hospital transfusion services, blood administration to patients, wastage of blood, 
transfusion-reaction management, opportunity cost of donor’s time all influence 
the overall costs of transfusions (Amin et al., 2004; Glenngård et al., 2005). 
Resources are, however, limited, and cost-effectiveness analysis can help 
rational decision-making in focusing future improvements in blood safety 
(Custer and Hoch, 2009). 
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AIMS OF THE STUDY 
The general aim of this observational study was to develop and establish a data-
gathering system for studying the epidemiology of blood transfusions in Finland 
(I) and to examine and compare transfusion practices in Finnish hospitals (II, 
III, IV, V). 
The specific aims were: 
1. To describe blood component (RBC, FFP, and PLT)-transfused patients in 
Finland and to compare transfusion practices in common elective surgical 
procedures between hospitals (I). 
2. To study FFP use and FFP transfusion practices in Finland, and to compare 
Finnish and international data (II). 
3. To determine the impact of RBC transfusions on hospitalization length in 
moderately anemic parturients (III). 
4. To describe the population of PLT-transfused patients in Finland, in particular 
those PLT recipients undergoing surgery (IV). 
5. To study the association between blood transfusion and ASA classification in 
surgical patients (V). 
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MATERIALS AND METHODS 
1. Finnish healthcare system and blood 
transfusion service 
Primary healthcare in Finland is organized by approximately 270 health centers 
providing outpatient medical care, inpatient care, and preventive services by 
doctors, mainly general practitioners, nurses and other medical professionals 
(Ministry of Social Affairs and Health, 2004). Inpatients treated in health center 
wards are usually elderly and chronically ill. 
Secondary healthcare is provided by 5 university hospital districts and 16 central 
hospital districts. Finland’s hospital districts include, besides university or central 
hospitals, also 40 other smaller specialized hospitals (i.e. district hospitals). 
Secondary healthcare services include inpatient and outpatient medical care by 
specialized doctors, nurses, and other healthcare professionals. 
Privately provided healthcare services consist mainly of outpatient care, and 
only a few private hospitals are available in Finland’s largest cities. 
The FRC BS is a non-profit, independently functioning unit of the Finnish Red 
Cross. It collects and produces blood and plasma products from blood that is 
donated entirely voluntarily, with no payment to the donors, who are Finnish 
residents. The Blood Service was Finland’s only blood-component supplier from 
1996 to 2003. In 2004, an FRC BS collaboration with Octapharma made it 
possible also to purchase solvent detergent FFP (Octaplas®) in Finland. 
2. Participants 
At the end of 2002, three university hospital districts and the FRC BS began a 
project for benchmarking and improving blood use practices in Finland (Mäki, 
2007). The aim was to create a national information system regarding 
transfused patients. Eight Finnish hospital districts joined from the beginning 
and two districts later. Hospital districts participated on a voluntary basis, with 
the expenses of creating the data system divided between participants and the 
FRC BS. Written informed consent was not required for observational and 
anonymous data registration. Steering group members appointed by the 
participating hospital districts approved the study. 
In 2002 and 2003 nine Finnish hospital districts participated in our study. Four 
of them were university-hospital-led (C, F, G, I) and five were central-hospital-
connected (A, B, D, E, H). Participating hospitals were located in the most 
heavily populated regions in Finland (Figure 8). Annually, these hospital districts 
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have about 620,000 inpatient episodes, constituting 63% of all inpatient visits 
provided by the Finnish secondary healthcare system. 
In 2004 and 2005, participants comprised four university hospital districts (C, F, 
G, J) and five central-hospital-connected districts (A, B, D, E, H). They manage 
about 64% of annual inpatient episodes. Due to the conversion by hospital I to 
an updated hospital administration system and because hospital district J joined 
later, their participants differed slightly from those in the 2002-2003 study 
period. 
Hospital districts C and E included several separately managed hospitals and 
therefore we reported these hospitals independently. In Finland, treatment of 
some special patients is centralized in university hospitals, this including organ 
transplantation, pediatric open-heart surgery, major burn injuries, allogenic 
bone-marrow transplantation, and acute leukemia. 
Figure 8. Participating hospitals and hospital districts, 2002-2005. 
 
3. Data collection 
Data were collected from hospitals, which fulfilled all technical requirements and 
could deliver all necessary data. In practice, hospitals were required to have a 
transfusion database, and included were all major transfusing hospitals. 
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Personal identification numbers were chosen for all patients transfused or 
potentially at transfusion risk: 1. patients for whom blood components (RBC, 
FFP, or PLT) were ordered (these patients were not necessarily transfused), 2. 
all surgical patients with procedure codes (NCSP, the NOMESCO Classification of 
Surgical Procedures, classification of surgical procedure, 2003) starting with A, 
B, C, D, E, F, G, H, J, K, L, M, N, P, Q, and Y, omitting patients with small or 
merely diagnostic procedures (i.e. codes starting with T, U, X and Z) and 3. 
patients with their main diagnoses as ICD-10, International Classification of 
Disease, 10th revision, 1999 C81-C96, D45-D47, D50-D77, O00-O99.8, P50-P61, 
S00-S99.9, T00-T07, T20-T23, T79-T98, and Z99.9. These diagnoses included 
patients with malignant disorders, anemia of any cause, obstetric disorders, 
fetal or neonatal hemorrhagic and hematological disorders, and burns or 
trauma. Collected personal identification numbers included, besides transfused 
patients, also patients to serve as controls for further use (for example, all 
obstetric patients). 
All data recorded under selected personal identification numbers were gathered 
from these hospitals’ pre-existing information registers. These systems were 
designed for administrative purposes (Musti, Tietoenator Oyj, Espoo, Finland; 
SAPO, OYS, Oulu, Finland), laboratory tasks (MultiLab, Mylab Oy, Tampere, 
Finland; OYSlab, OYS, Oulu, Finland), operating room responsibilities (ToTi, WM-
Data Novo Oyj, Espoo, Finland; LESU, OYS, Oulu, Finland; Musti, Tietoenator 
Oyj, Espoo, Finland), and hospital blood center work (Vertti, MyLab Oy, 
Tampere, Finland; OYSlab, OYS, Oulu, Finland). All data recorded in the FRC BS 
blood banking task program (Progesa; MAK-SYSTEM, Paris, France) were also 
included for quality verification purposes. 
Patients´ personal identification numbers were encrypted by a coding computer 
program (DWcrypt, Datawell Oy, Espoo, Finland). This coding program used a 
different password for each hospital district. This security measure ensured that 
a patient treated in two hospital districts had two different database 
identification numbers, ensuring anonymity. Passwords were entrusted to only 
one person from each hospital district to guarantee anonymity. 
Personal identification numbers and time stamps in the data assisted in pre-
processing and assembling all information gathered into hospital episodes. The 
final hospital episode comprised one patient visit to one medical specialty. Pre-
processing and assembling of the program (VOK pre-processing, Datawell Oy, 
Espoo, Finland) combined 90 originally collected transfusion-related variables 
into 149 parameters to describe each episode (Optimal use of blood 
components, 2006). The main groups of variables were patient demographics 
(gender, age), place of treatment (hospital, ward), diagnoses (primary, several 
secondary, permanent, and operation-related diagnoses), surgical procedures 
(operation length, urgency, ASA-classification; Table 2), ordered and transfused 
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blood components (estimated transfusion time, urgency, blood group), 
laboratory test values (lowest and highest hemoglobin, PLT values), as well as 
hospital admission and discharge variables (medical specialty, length of hospital 
stay, discharge status). 
Table 2. American Society of Anesthesiologists (ASA) Physical Status Classification. 
 
Year of hospital episode was defined by the starting date of the hospital visit. 
Thus, some of the previous years’ visits continued into the next year. 
The central database was saved to a remote server and accessed via the 
Internet by passwords. 
4. Blood components 
All blood components transfused to adults or children (RBC, FFP, PLT, 
cryosupernatant, white cells, whole blood, reconstituted blood) were gathered 
into the database. Blood components were expressed as units. Adult PLTs were 
described as a product (i.e. one PLT product containing four units of PLTs) in 
Study IV to be internationally clear. The main features of blood components 
(RBC, FFP, and PLT) used in our study are described below. 
The main RBC product has been leukodepleted from the beginning of 2003, and 
one unit of RBCs has a volume of roughly 300 mL. It is manufactured from 
whole blood by centrifuging, removing the plasma, adding 100 mL of SAGM 
solution (sodium chloride-adenine-glucose-mannitol) and filtering. RBCs for 
small children are prepared by dividing an adult’s product into three parts. One 
product, adult’s or child’s, is equal to 1 unit of RBC. 
During the study period, the main FFP product was whole-blood–recovered 
leukodepleted fresh plasma frozen within 6 hours of donation and stored at 
<30°C. One product for adults was of approximately 270 mL containing 1 
unit/mL of all normal plasma coagulation factors and physiologic anticoagulants. 
Plasma used for children was collected by apheresis. A single-donor apheresis 
plasma dose was divided into nine children’s products (volume, 50 mL). One 
product, adult’s or child’s, is equal to 1 unit of FFP in the present study. The 
Octaplas® pharmaceutical product currently used was not included in any 
results of this study. 
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The main PLT product (98.5%) is prepared using the buffy-coat procedure and is 
preserved in PAS II-solution (sodium citrate, sodium acetate, sodium chloride, 
water). All PLTs are leukodepleted. One product of PLTs contains for practical 
purposes PLTs from four donors. One therapeutic PLT component thus contains 
4 units. The volume of the PLT product is about 320 mL. The children’s PLT 
product also contains 4 units of PLTs, but in a volume of 200 mL. Children’s 
products were included in the results of this dissertation–although omitted from 
Study IV for consistency. 
When costs of blood components were calculated, the price of each product was 
used separately (Table 3). Prices in different years were used, with no additional 
expenses (HLA typing, HPA typing, phenotyping, or emergency duty prices) 
taken into account. The cost of one RBC unit increased in 2003 when the RBC 
product most used became leukodepleted. 
Table 3. Costs of the most frequently used adult blood components in Finland. 
 
5. Quality assurance 
Hospitals assisted in a systematic audit of data variables. For each hospital the 
audit was performed each year. Rough, unprocessed electronic data were first 
audited to insure a correct collection process and the collection of all desired 
variables. Then the pre-processed data to agree assembling and later the 
combined data were checked separately. The audit included such tasks as 
unifying code sets and comparing collected data to FRC BS sales figures and to 
figures reported by individual hospital districts (asked independently from each) 
and official national statistics (FHDR). Furthermore, distributions of processed 
variables were thoroughly studied, with data comparison between study years. 
The final audit included random sampling of the data for deviations. All 
deviations discovered during the auditing process were scrutinized further. 
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6. Study characteristics 
 
Five studies were performed, based on transfusion data (Table 4). 
 
Table 4. Study characteristics. 
 
 
 
 
7. Statistical analyses 
All patients meeting the requirements were included. Patient populations were 
limited by diagnosis and surgical procedure codes. 
The Ecomed Analyzer reporting program (version 6, Datawell Oy, Espoo, 
Finland), SPSS (version 12.0.1, SPSS Inc., Chicago, IL, USA) and R (Version 
2.5.1 and Version 2.7.1, R Foundation for Statistical Computing, Vienna, 
Austria) served for analysis of the data. 
For statistical analysis, ANOVA was used to calculate differences in blood 
component usage and costs (I) and to detect differences in duration of hospital 
stay (III). The Mann-Whitney U-test allowed analysis of differences in the last-
measured Hb values (III) as well as differences in transfusion dose of PLTs 
between genders (IV). The T-test allowed a search for differences in transfusion 
age between genders (IV). Odds ratios were calculated to study association of 
PLT transfusion frequency and gender (IV). A logistic regression model was 
 41 
constructed to study the probability of receiving RBCs during arthroplasty, and a 
scoring system was constructed from the odds ratios for each predictor variable 
(V). To check the validity of the model, receiver operating curves were 
constructed (V). 
The results were expressed as mean ±standard deviation or median and range. 
A probability less than 0.05 was considered significant. 
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RESULTS 
1. Validation of data (I) 
In 2002 and 2003, 97% of the most commonly transfused blood components 
(adult RBC, FFP, PLT) sold by the FRC BS to the participating hospitals were 
found by comparison between hospital data and FRC BS sales information. RBC-
use figures reported by participating hospitals produced a match in 94% of 
cases in a comparison with our established data system. Most hospitals acquired 
their data from the blood bank or invoicing systems. The number of primary 
knee replacement operations reported by the Finnish Hospital Discharge 
Register and our data matched by at least 98% in hospitals with more than 200 
hip or knee operations per year. A random check, matching written data on 
primary hip replacement operations from one of the participating hospitals 
(Surgical Hospital in Helsinki) with collected computerized data, found a match 
in 99% of cases. ASA grade was recorded for 86% of procedures during 2002 
and 2003 and for 90% during 2004 and 2005. The integrity of our data appears 
to be sufficient for comparative purposes and epidemiological research. 
2. Finnish transfusion practices 
2.1. Finnish blood component recipients (I, II, III, 
IV, V) 
Data covered 117,248 hospital visits with transfusion (Table 5). All patients 
irrespective of age were included in the results of this dissertation (unlike in 
Study IV) for simplicity. Comparison with FRC BS sales figures revealed that our 
data included 54% of RBC sold during the study period, 71% of FFP units sold 
and 70% of PLT products sold (unpublished data from study I). 
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Table 5. Study patients with transfusions 2002-2005. One individual patient can belong 
to several groups. (Some of these data are unpublished from Studies I and IV). 
 
Age of transfused patients 
Most Finnish blood component-transfused patients were elderly (52% over 64), 
mean age 60 (SD 23) and median 65 (range 0-102); 6% of those transfused 
were under 16 and received 10% of the blood components. 
FFP recipients were younger than all transfused patients; their mean age was 53 
years (SD 27), median 62 (range 0-102). The percentage of FFP-transfused 
patients under age 16 was 16%. 
Surgical PLT-transfused patients were also younger than blood recipients 
overall, at a mean age of 54 (SD 24.4) and median 60 (range 0-97). PLT-
transfused men undergoing surgery were older than women (men 55, SD 23.0; 
women 52, SD 25.9; p<0.001). Only 8% of surgical PLT recipients were aged 
under 16. In short, blood recipients are most often elderly, but FFP and PLT 
recipients are younger than those blood-(or RBC-) transfused on average. 
 
Transfused patients and gender 
Blood component (RBC, FFP, PLT) -transfused patients were more likely to be 
women (56%). Males, however, received most of the blood components (54%). 
FFP recipients, in contrast, were more often men (58%), and men received also 
the majority of FFP units (60%). PLT-transfused surgical patients were also 
more frequently men (61%). This finding was statistically significant (p<0.001). 
Operated men also received most of the PLT components (60%), but between 
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genders, dosage of transfused PLTs was equal (mean dose of PLTs for men 
15.02, for women 15.5; p=0.58). 
 
Diagnosis of transfused patients 
Half of all blood components (RBC, FFP, PLT) were transfused to patients with a 
hematological malignancy (20% of units), cardiovascular disease (16%), or 
trauma (13%). The greatest amounts of blood components were transfused to 
patients with myeloid leukemia (8% of units) and coronary heart disease (6%). 
Patients with cardiovascular (26% of units) or gastrointestinal (17%) problems 
or trauma patients (16%) received the largest numbers of FFP units. The most 
common main diagnoses found among hospital visits involving FFP were: 1. 
coronary artery disease (4% of transfused FFP units), 2. atherosclerosis of 
arteries of extremities (3%), and 3. alcoholic cirrhosis of the liver (2%). The 
highest mean number of FFP units (5 units per hospital visit) was transfused to 
gastrointestinal patients, and 26% of FFP-transfused patients had cardiovascular 
disease as their main diagnosis. 
Overall, the largest amounts of PLTs went to patients with malignant diseases of 
the blood as the main reason for their hospital stay (46% of PLTs). About 1% of 
surgical patients received PLTs, and perioperatively PLTs were mainly transfused 
to patients with cardiovascular problems (30% of transfused units to surgical 
patients), trauma (18% of units), and patients with digestive-system diseases 
(12% of units). The greatest number of PLTs per hospital visit involving a 
surgical procedure went to hematological cancer patients (mean 46 units per 
hospital visit). 
 
Transfused patients and type of surgery 
Surgical patients most often received blood components (RBC, FFP, PLT) in 
connection with operations involving the musculoskeletal system (27% of units 
transfused perioperatively; 34% of transfused surgical patients), gastrointestinal 
system (20%), or heart and major thoracic vessels (18%). The highest amounts 
of blood components were transfused to CABG patients (7% of perioperatively 
transfused units) or surgically treated hip-fracture patients (6%). The largest 
number of blood components per operative hospital visit was transfused to 
patients with infrarenal aortic aneurysm (27 units per hospital visit). 
The majority of FFP were transfused perioperatively (67% of transfused units). 
The highest amounts of FFP were transfused during gastrointestinal surgery 
(25% of transfused FFP units), heart and major thoracic vessel surgery (23%) 
and musculoskeletal surgery (16%). Gastrointestinal patients received the 
largest number of FFP units per one hospital visit (6 units). Of FFP-transfused 
surgical patients, 25% underwent heart surgery. 
Perioperatively transfused PLTs went to patients operated on for digestive 
system disease (25% of perioperatively transfused units), heart disease (25% of 
units), and musculoskeletal problems (14% of units). Most of these PLT 
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recipients operated on had coronary surgery (15%) or aortic valve replacement 
(5%). 
 
Transfusion of PLTs and ASA grade 
PLT-transfused ASA grade 1,2, or 3 patients were most often orthopedic or 
trauma patients (37% of hospital visits with transfusion), ASA-4 patients usually 
had heart surgery (7% visits with transfusion) and ASA-5 patients most often 
underwent gastrointestinal surgery (0.6% if visits with transfusion). ASA grade-
3 patients received most of the blood components (36%). 
PLT-treated operated men had a worse preoperative status than did women, 
judged by ASA grade (Figure 9). These men stayed longer in the hospital than 
did women (men 11 days, range 1-356; women 9, range 1-288) and had higher 
in-hospital mortality (men 13%; women 11%). 
 Figure 9. Rate of PLT-transfused surgery patients by gender and ASA-grade. 
 
 
 
 
 
 
 
 
2.2. Blood usage (I, II) 
Blood component usage differed between 2002 and 2003. Fewer blood 
components were transfused in 2003, and the number of transfused patients 
and hospital visits with transfusion dropped between those years (Table 6). 
Moreover, the average number of transfused blood components during hospital 
visits involving transfusion decreased. Reductions were concentrated among 
surgical patients. Perioperatively, fewer RBCs were transfused but an increase 
occurred in FFP use (Table 6). 
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Table 6. Blood use in Finland years 2002 and 2003. 
 
2.3. Transfusion trigger practices (II, IV) 
Coagulation (PT, INR, or APTT) associated with FFP transfusion was measured in 
only 66% of hospital visits (Figure 10), although coagulation parameters were 
checked somewhat more often during hospital visits including surgery (68%). 
The median for highest INR measurement rate during a hospital visit with FFP 
transfusion was 2 (range 0.8-11; mean 2.5). Furthermore, in 19% of hospital 
visits with FFP transfusion the highest measured INR was below 1.5. 
Figure 10. Rate of fresh frozen plasma (FFP) recipients by INR testing in 2002 and 
2003. 
 
PLT count was measured at least once during almost every hospital visit with 
PLT transfusion and surgical procedure (99.5%) (unpublished data from Study 
IV). The mean of lowest PLT count in operated patients was 73x109/L (SD 
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53X109/L). The difference between admission PLT count and lowest measured 
PLT count during the hospital visit suggests a higher percentage of transfusions 
for therapeutic than for prophylactic indications (Table 7). Transfusion-threshold 
PLT count varied between specialties and hospitals (Figure 11, Table 6). The 
difference between hospitals was statistically significant (p<0.001). 
Table7. Lowest measured PLT counts during hospital visits and PLT transfusion by 
medical specialty in patients undergoing surgery (2004 and 2005, unpublished data from 
Study IV). 
 
 
Figure 11. Mean and SD of lowest measured PLT count during hospital visits of PLT-
transfused surgical patients (2004 and 2005, unpublished data from Study IV). 
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2.4. Dosage of blood components (I, II) 
RBCs and FFP were transfused in paired and PLTs in 8-unit doses (Figure 12). 
Two units of RBC were given to 45% of RBC recipients, 36% of FFP recipients 
received a two-unit dose of FFP, and 45% of PLT-transfused patients receive 8 
units of PLTs. The practice of two-product dosing is evident repeatedly in several 
subgroups of adult surgical patients (unpublished information). 
Figure 12. Rate of hospital visits with red blood cell (RBC), platelet (PLT), and fresh 
frozen plasma (FFP) transfusion by number of transfused blood units. Years 2002 and 
2003. 
 
2.5. Costs of blood components (I) 
Hematological malignancy and cardiovascular-disease patients generated the 
highest costs for blood components (19-26% of blood costs, 15-16%, 
respectively) (I). For surgical patients, most blood-component costs came from 
orthopedic patients (26-28% of costs involving surgery). 
3. Comparison of transfusion practices among 
Finnish hospitals (I, IV) 
We found variation in blood-component usage among hospitals. Percentage of 
RBC-transfused knee-replacement patients ranged between participants from 
13% to 57% (Figure 13), and the average number of transfused RBC units 
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varied (mean 0.8 (SD 1-3; median 0, range 0-16). Variation in RBC-component 
use was confirmed in transurethral resection of the prostate (TURP) and 
hysterectomy (Table 8). Costs of RBCs per 100 operations showed multiple 
differences between institutions (I). PLT use in CABG patients also showed 
variability (IV). 
Figure 13. Mean of transfused red blood cell (RBC) units and percentage of transfused 
patients in unilateral knee replacement surgery for arthrosis in Finnish hospitals. Years 
2002 and 2003. Hospital districts C and E include several separate hospitals. 
 
 
 
 
 
  50 
Table 8. Red blood cell (RBC)-transfused patients undergoing transurethral resection of 
the prostate (TURP) and hysterectomy. Years 2002 and 2003. Hospital districts C and E 
include several separate hospitals. 
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4. Impact of red blood cell transfusion in a 
selected group of parturients (III) 
Study III evaluated RBC transfusion practice in a selected group of parturients. 
Patients admitted for vaginal delivery and having the lowest measured Hb value 
between 70 and 100 g/l and receiving 0 to 2 units of RBCs were compared in 
different Hb groups: 70 to 79 g/l, 80 to 89 g/l and 90 to 100 g/l. Only 
uncomplicated deliveries were included, and patients with surgical procedures or 
with recorded diagnoses affecting tolerance of anemia (for example cardiac 
disease) or increasing risk for bleeding (for example eclampsia) were excluded. 
The percentage of transfused parturients in this group was 13% (70-79 g/l, 
70%; 80-89 g/l, 32%; 90-100 g/l, 1%). Mean duration of hospitalization did not 
differ statistically significantly between studied groups (70-79 g/l, for 5.4 days; 
80-89 g/l, 5.2 days; 90-100 g/l, 5.1 days; p=0.33) or between transfused and 
non-transfused parturients within groups 70 to 79 g/l and 90 to 100 g/l (70-79 
g/l, for transfused 5.4 days and non-transfused 5.2 days, p=0.50; 80-89 g/l, 
5.1 days and 5.5 days, p=0.07; 90-100 g/l, 5.1 days and 5.4 days, p=0.54). 
Hospitalization of these anemic patients (Hb from 70 to 100 g/l) was distinctly 
longer than the mean stay of Finnish parturients (mean 5.2 versus 3.5 days). 
5. Correlation between American Society of 
Anesthesiologist’s (ASA) Physical Status 
Classification and transfusions (IV, V) 
ASA grade correlated positively both with the number of transfused blood 
components and the percentage of transfused surgical patients, with more 
severely ill patients receiving more and also more frequent transfusions (V). 
Correlations were similar with all blood components when studied separately 
(RBCs, FFP, and PLTs). Especially those patients belonging to ASA grade groups 
3 to 5 received more and also frequent blood components. Subgroup analysis of 
elective primary hip arthroplasty patients revealed a similar correlation with RBC 
transfusion and ASA grade (V). 
In the general surgical patient population, RBC units ordered before surgery 
went more often to patients belonging to a higher ASA grade (unpublished data, 
Fig. 14). On average, 49% of all RBC units ordered were transfused at that time 
in Finland (Fig.14). 
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Figure 14. Red blood cell (RBC) units ordered for surgery; percentage of administered 
and returned RBC units by ASA physical status classification (unpublished data from 
study V). 
 
There arose, however, a difference in correlation between genders in PLT-
transfused patients. Male patients of a higher ASA grade group received PLTs 
more often than did women (the percentage of PLT-transfused men: ASA 1, 
40%; ASA 2, 44%; ASA 3, 60%; ASA 4, 66%; ASA 5, 71%; women: ASA 1, 
60%; ASA 2, 56%; ASA 3, 40%; ASA 4, 34%; ASA 5, 29%). Women, compared 
to men, thus received PLT transfusion more often at lower ASA grades. 
An analysis predicting RBC transfusion in 3,271 primary total hip- replacement 
patients was performed, with a logistic regression model for RBC transfusion 
constructed and validated. The final prediction model included variables: ASA (I-
II, III-IV), age (under 60 years, 61-70, 71-90, over 80), gender and 
preoperative hemoglobin value (under 90 g/l, 91 to 110 g/l, 111-130 g/l, 131-
150 g/l and over 150 g/l). The area under the receiver operating curve for the 
resulting model in the training and validation data sets was 0.7 and 0.69, 
respectively. RBC transfusions were positively correlated with ASA grades III 
and IV, with age, female gender, and preoperative anemia. The percentage of 
RBC-transfused hip-replacement patients was high (65%). A clinical prediction 
rule for RBC transfusion was developed from the odds ratios generated by this 
model. Our scoring system identified patients with either high (predicted 
transfusion risk over 65%) or lower risk (predicted risk under 40%) for RBC 
transfusion. 
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DISCUSSION 
1. Key results and strengths of the study  
The data-gathering system established for this study was the first published 
national, annually accumulating database combining easily accessible 
information from several computerized registers to study blood transfusion 
recipients (I). Existence of a permanent, lifelong personal identification number 
used only in the Nordic countries enabled the combination of information 
collected from various sources. This system allowed us to investigate Finnish 
transfusion recipients and practices and to gather an information bank for our 
local healthcare professionals for benchmarking. This transfusion material 
included over 100,000 hospital visits with blood transfusion. 
Our study register concentrated on more detailed information on the transfusion 
procedure and on transfusion recipients themselves. We also gathered blood-
donation and detailed blood-component information, but did not use this 
information in our studies. These data were gathered only for quality assurance. 
In the same time period, published nationwide Scandinavian studies using a 
similar data-gathering process approached the subject of transfusions differently 
(Edgren et al., 2006; Kamper-Jørgensen et al., 2009). They sought to monitor 
the long-term outcome of transfusion recipients and included in their own 
transfusion register data values affecting mortality (death and birth variables, 
blood donation and component variables, cancer variables). The Danish 
Transfusion Database, which has been nationwide since 2006, includes similar 
transfusion-related information as the Finnish database presented to assess 
transfusion practices (Dansk Transfusionsdatabase, home page on the Internet). 
Blood transfusion-recipients’ characteristics were similar to those of earlier 
international studies. 
Our study on FFP use practices (II) was the first published national study 
including all FFP recipients (surgical and medical patients and also children) 
reporting also each FFP recipient’s diagnosis and surgical procedures. 
Furthermore, our study reported figures of FFP use during surgery, giving 
baseline numbers for international comparison. 
Unnecessary blood transfusions do occur also in Finland. Transfusion of 1 to 2 
units of RBCs to moderately anemic parturients did not shorten the length of 
their hospital stay, suggesting possible over-usage of RBC in certain situations 
(III). 
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Most of the descriptive information on PLT use comes from hematological 
patients. Our national study reported perioperative use of PLT adding knowledge 
of characteristics of these blood recipients (IV). 
Our comprehensive study population allowed us to study the association 
between blood transfusions and the more subjectively assessed variable ASA 
grade (V). Increased preoperative morbidity increased the possibility of 
receiving blood transfusion. 
2. Generalizability and limitations of the study 
The participating hospitals, situated in the most populated regions of Finland, 
constituted almost two-thirds of Finnish annual in-hospital visits (63% in the 
years 2002 and 2003; 64% in 2004 and 2005). Our data did not include all 
Finnish hospitals. No hospital districts without the technical ability to send 
computerized transfusion data were included. Furthermore, our study covered 
no Finnish primary heath care centers, nursing facilities, or private-sector 
hospitals. Neither did we include less frequent blood-component users, for 
example home-performed transfusions. Blood use at these less acute institutions 
is, however, uncommon and limited mainly to transfusion of RBCs. Our data 
included over 50% RBC units sold and roughly 70% of FFP and PLT products 
sold during the data period. Our study hospitals included 5 out of 5 of the 
Finnish university hospitals and a smaller portion of the other Finnish hospital 
districts. 
From the methodological perspective, an obvious limitation to this study is that 
it is a register-based research. The focus of the registers differs from that of our 
study aims, limiting the data. Multiple sources of input error exist. For example, 
data are recorded in the information systems by numerous professionals with 
varying dedication and experience to fill in the required data. There may be a 
few cases not recorded or accidentally cases recorded multiple times. 
Mechanical, logical, and copying errors add to data inaccuracy. Subjectivity in 
recording ASA grade deserves to be mentioned separately as a variable 
limitation. Furthermore, these registers do not include all information necessary 
for transfusion research. For example, patient’s weight and height or values of 
point-of-care laboratory measurements are absent. 
Auditing is a prerequisite for register-based research. Technical data collection 
from different registers may fail, and pre-processing may produce technical 
errors. Hospitals have their own modifications or additions to the otherwise 
uniform software, which make the defining of, for instance, code sets laborious. 
For this research, over 2,000 code mappings were made manually to create 
uniform code sets (unpublished information). However, once this task of 
ensuring uniformity is completed successfully, analysis of data in the following 
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years requires much less effort. Validation is, nevertheless, needed on every 
occasion that new information is collected and especially when any changes are 
made to the software. The quality of the data gathered is assumed to improve at 
every collection. The accuracy of the recorded diagnosis and surgical procedures 
can be audited by comparison of the gathered information between handwritten 
hospital data or data collected in other available sources. Only random samples 
for comparison were taken between handwritten data (Surgical Hospital in 
Helsinki) and one easily accessible source of computerized data (the Finnish 
Hospital Discharge Register). An audit was done concerning arthroplasty 
patients. 
Because of the limitations in study material collection, single or small groups of 
treatment episodes cannot be compared or examined separately. It is essential 
that the amount of information studied is large enough. Only the most accurate 
data variables estimated by the validation process are appropriate for research. 
Similar data gathering processes and validation results from Danish researchers 
indicate the rationality of our approach. Validation of electronic patient 
information gathered from six different computerized registries in Denmark 
found 98% integrity of all blood-component transfusions, and 95% of them did 
connect with a main diagnosis (Titledstad et al., 2002). Danish data-gathering 
and validation processes were similar to ours (Titlestad, personal 
communication). Both groups used permanent personal identification numbers 
provided by national authorities for connecting transfusion-related data from 
different information systems. 
3. Blood component recipients 
Age of transfused (RBC, FFP, PLT) patients 
Other studies confirm the finding that elderly patients represent the majority of 
all transfusion recipients (Mathoulin-Pelissier et al.2000; Tynell et al., 2001, 
2005; Kamper-Jørgensen et al., 2009; Appendix 2). The aged patients in our 
study received a larger proportion of transfused blood components than in the 
Zimmermann group study (1997), but that German study was conducted in one 
study hospital only. Results from other Nordic countries (Denmark and Sweden), 
on the other hand, resembled our findings (Kamper-Jørgensen et al., 2009). In 
the present study, children (6.2% of transfused patients) received about 10% of 
all transfused blood components, a finding agreeing with a finding in the U.K. 
(Stanworth et al., 2002). Related figures were lower in Denmark, Sweden, and 
Spain, but higher in the USA (Vamvakas and Goldsten, 2002; Kamper-Jørgensen 
et al., 2009; Bosch et al., 2011). Dissimilarities in the data sample and in cut-off 
ages might explain these differences. 
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Ages of FFP and PLT recipients 
A Finnish finding of almost half of FFP units being transfused to patients over 
age 60 differs from the U.K. and Danish practice, where a larger proportion of 
FFP goes to this elderly patient group (Cobain et al., 2007; Appendix 2). The 
cut-off ages do not match those of studies from the USA, Australia, and the 
Netherlands, but their usage practices seem similar to ours (Vamvakas and 
Taswell, 1994; Cobain et al., Australias' data, 2007; Borkent-Raven et al., 2010; 
Appendix 2). In a Dutch study with age-grouping in children similar to that in 
our study, children received fewer of all transfused FFP units, but the patient 
population included only academic hospitals (Borkent-Raven et al., 2010). 
Children’s cut-off age varied among other reported FFP-transfusion data, 
explaining the differences (0-9 and 10-19 years for Cobain et al. compared to 0-
15 years in the present study) (Cobain et al., England’s and Denmark’s data, 
2007). We found the Finnish FFP- and PLT-transfused patients to be younger 
than transfused patients in general, agreeing with other studies (Cook and Epps, 
1991; Tynell et al., 2001; Greeno et al., 2007; Cobain et al., 2007; Wells et al., 
2009; Borkent-Raven et al. 2010; Stanworth et al., 2011). 
 
Transfused (RBC, FFP, PLT) patients and gender 
That women are being transfused more often with blood components 
(altogether) than are men is in agreement with others’ findings (Whyte, 1988; 
Mathoulin-Pelissier et al., 2000; Tynell et al., 2001, 2005; Titlestad et al., 2002; 
Kamper-Jørgensen et al., 2009; Madsen et al., 2010; Appendix 3). Because RBC 
recipients comprise most of our study patients (Table 4), this finding could at 
least in part be explained by female patients’ having initially lower base-line Hb 
concentrations and red cell mass. When patients with the same Hb 
concentrations (g/l) are compared, patients with a lower blood volume, such as 
females, bleed less to drop to the same Hb count than does a patient with a 
higher blood volume. This may increase the susceptibility to transfusion of 
patients with smaller body sizes. However, one study in patients undergoing 
CABG surgery showed that female gender was still significantly associated with 
RBC transfusion even when the genders compared were within the same 
subgroups for age, weight, duration of surgery, and preoperative hematocrit 
(Shevde et al., 2000). Age standardization in one Danish study resulted in 
evidence of men’s higher transfusion prevalence rates (one-year prevalence rate 
6.8/1,000 for men and 6.3/1,000 for women) (Madsen et al., 2010). Differences 
in age distribution between genders are accounted for when comparing 
transfusion databases. There is evidence supporting a role for sex hormones in 
altering the hemostatic balance (Lawrence et al., 1995; Mendelsohn, Karas, 
1999). For example, use of oral contraceptives is clearly associated with an 
increased risk for thrombotic events. However, due to the complexity of the 
mechanism involved in the coagulation system, a gender difference in one or 
more hemostatic components may not lead to an apparent difference in overall 
 57 
hemostasis (Capodanno, Angiolillo, 2010). Differences in hemostatic balance 
between genders may not explain the gender-specific differences in the 
likelihood of transfusion. 
 
FFP recipients and gender 
That more men were transfused with FFP, and men received a larger proportion 
of FFP than did women agrees also with several other results (Cook and Epps, 
1991; Zimmermann et al., 1997; Cobain et al., 2007; Wells et al., 2009; 
Borkent-Raven et al., 2010; Bosch et al., 2011; Appendix 3). Men are over-
represented in certain patient groups requiring FFP (for example CABG, 
gastrointestinal bleeding, and trauma) (unpublished information from Study II), 
and this finding may also result from their larger body size and also reflect 
dosing by weight. 
 
PLT recipients and gender 
Finnish male patients received more of the PLTs used perioperatively and 
received them more often than did female patients. Even though we studied 
only a particular subgroup of PLT recipients, other work confirms this finding 
(Cook and Epps, 1991; Zimmermann et al., 1997; Cobain et al., 2007; Wells et 
al., 2009; Borkent-Raven et al., 2010; Bosch et al., 2011; Appendix 3). This 
observation might in part be explained by the finding of male PLT recipients’ 
having a worse preoperative status than did women, as well as their greater 
body size, and may thus reflect PLT dosing by weight. 
 
Diagnosis of transfused patients 
In Finland, cancer and cardiovascular disease patients received most of the 
blood components, in agreement with Swedish findings (Tynell et al., 2005). 
Circulatory or digestive system diseases represented in our study the most FFP-
transfused diagnostic groups, as in five other studies (Cook and Epps, 1991; 
Cobain et al., 2007, Denmark’s data; Wells et al, 2009; Borkent-Raven et al., 
2010; Bosch et al., 2011; Appendix 4). Our findings differed from French, 
German and Korean findings including in their analyses either a smaller sample 
of patients or fewer hospitals (Zimmermann et al., 1997; Mathoulin-Pelissier et 
al.2000; Lim et al., 2004). This dissimilarity probably therefore reflects a 
difference in patient material. As in Denmark and Spain, also in Finland the most 
common diagnosis of FFP-transfused patients is coronary artery disease 
(Titlestad et al., 2001; Bosch et al., 2011; Appendix 5). 
 
Transfused patients and type of surgery 
Our data included fewer patients with coronary artery surgery and blood-
component (RBC, FFP, PLT) transfusion than did a Swedish study (7% versus 
14%) (Tynell et al., 2005). The percentage of transfused femoral fracture 
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patients was almost double ours in the Swedish data (6% versus 
11%)(Appendix 6). 
Two-thirds of FFP units were transfused to patients having surgery, which 
matched the findings of Cook and Epps (1991), and two-thirds of FFP recipients 
were surgical patients. 
About 10% of our patients undergoing CABG received PLTs. PLT use during 
CABG was similar to that of previous findings (Sirchia et al., 1994; Kytölä et al., 
1998; Stover et al., 1998). 
4. Blood component usage 
This snapshot of Finnish blood transfusion use shows a trend towards a decrease 
in RBC use in contrast to FFP consumed. Annually PLT transfusion rates seem to 
vary more (I, Table 4). Variation in overall blood use between the years studied 
result from various causes, arbitrary or otherwise. 
Adequate comparison of Finnish blood component usage with international 
usage requires accepted and uniformly defined attributes. At the moment, 
published statistics are inconsistent. 
The FRC BSs´ annual sales figures confirm our finding of decreasing RBC use in 
Finland (Figure 1). In contrast to this, the trend in many countries has been 
toward an increase. The RBC transfusion trend in the USA in 2001 compared 
with 1999 shows a large increase, differing from our figures (Sullivan et al., 
2007). This rising trend of RBC use in the USA seems to be continuing (National 
Blood Collection and Utilization Survey Report, 2009). A significant part of RBC 
use variation per capita can be explained by differing age distributions of 
populations, because RBC transfusion frequency increases with age (Ali et al., 
2010). 
5. Transfusion trigger practices 
5.1. Transfusion of fresh frozen plasma 
New guidelines recommend transfusing FFP guided by coagulation parameters 
for assessment of the need and the efficacy of FFP transfusion (O’Shaugnessy et 
al., 2004). Our study results indicate that these guidelines are not followed by 
clinicians (II). This Finnish finding agrees with those of a European study 
(Sirchia et al., 1994). In the Sanguis study, PT levels were measured in only 
16% of FFP-transfused surgical patients. Our result showed wider acceptance of 
coagulation-test monitoring with FFP transfusion (about 66%). However, this 
Finnish finding differed from Australian findings from one tertiary hospital; in 
their clinical audit study, 92 to 97% of FFP recipients had coagulation 
parameters available or only requested (Hui et al., 2005). Better acceptance of 
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coagulation screen tests (93%) was also observable in the U.K. (Stanworth et 
al., 2011). The difference from the Finnish figures may involve dissimilarities 
between studied institutions and may also involve availability of the coagulation 
tests or different implementation of FFP transfusion guidelines. 
Similar results to our Study II were reported by the ANZICS Group in an 
intensive-care patient group of 874 from Australia and New Zealand (Blood 
Observational Study Investigators of ANZICS Clinical Trials Group, 2010); 26% 
of FFP transfused did not agree with the national guideline cut-off value of INR 
1.5. Adbel-Wahad et al. (2006) concluded in their study of FFP-transfused 
patients with a pretransfusion INR between 1.1 and 1.85 that in less than 1% of 
the patients did the INR level normalize, and only 15% showed a correction at 
least half-way to normal with FFP transfusion, regardless of the number of FFP 
units transfused. Cheng and Sadek (2007) and Stanworth et al. (2011) found 
similar results. These study findings do not justify FFP transfusion in nearly one-
third of Finnish FFP-transfused patients with mild coagulopathy. 
5.2. Transfusion of platelets 
Our unpublished data show that nearly all Finnish surgical PLT recipients had 
PLT counts available. This agrees with the Australian figure (Hui et al., 2005). 
Our mean pretransfusion PLT count in surgical patients (73x109/L) agrees with 
present guidelines, which recommend PLT dosing at trigger values of 50 to 
100x109/L depending on type of surgery (Samama et al., 2006). Those in 
cardiac and thoracic surgery specialties seem, however, to apply PLT transfusion 
thresholds higher than recommended (Table 4). 
The PLT count triggering PLT transfusion in surgical patients was higher in our 
study than in the study of Arnold et al. (2006) in ICU patients (therapeutic 
trigger 51x109/L, prophylactic trigger 41x109/L). They excluded trauma, 
orthopedic, and cardiac-surgery patients, which explains at least part of this 
dissimilarity. Cameron et al. (2007) studied 25 surgery patients of 464 receiving 
PLTs in a referral hospital in Canada. They found the mean pretransfusion PLT 
count to be 84.5x109/l, slightly higher than in our patients. In Australia and New 
Zealand, a multicenter study of 874 ICU patients showed a mean transfusion 
PLT count of 67.0x109/l (Blood Observational Study Investigators of ANZICS 
Clinical Trials Group, 2010). They concluded that 53% of PLTs were not 
transfused adherent according to national guidelines (Council NHAMR, 2001). 
This dissimilarity may involve differences in the type and number of patients 
stemming from the differing profiles of the participating hospitals. 
PLT transfusion are required when a patient is severely thrombocytopenic or 
bleeding due to platelet dysfunction. Transfusion of platelets has been 
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associated with increased risk for in-hospital mortality in massively transfused 
patients according to Rose et al. (2009), who discussed whether platelet 
transfusion per se influences mortality during massive transfusion or only 
reflects the severity of patients’ underlying condition. Our findings support the 
latter in male patients (IV). Unfortunately we did not study massively transfused 
patients separately to find the possible association between the 1:1 transfusion 
ratio of FFP:RBC and lower in-hospital mortality, as suggested by Rose et al. 
(2009). One retrospective study of leukemia patients over a 10-year period 
found that the higher the dose of transfused platelets, the lower the survival in 
leukemia (Blumberg et al., 2008). Those patients receiving higher doses of PLTs 
required more and other transfusions as well. This finding suggests that patients 
receiving more PLTs need more chemotherapy and longer treatments to bring 
their leukemia into remission, reflecting severity of the disease (Blumberg et al., 
2008). PLT transfusion affecting mortality during cardiac surgery is a study topic 
(McGrath et al., 2008). A retrospective study from Cleveland included 32,298 
patients undergoing CABG, isolated valve, or combined CABG valve surgery, all 
requiring cardiopulmonary bypass. After propensity matching analysis, PLT 
transfusion did not confer an independent increased risk for adverse events. PLT 
transfusion did not lead to increased morbidity, neither in heavily RBC-
transfused cardiac surgery patients nor in patients receiving no RBC 
transfusions. 
6. Dosage of blood components 
6.1. Dosage of red blood cells 
RBCs being transfused in paired units in Finland probably arises from a 
traditional rule of thumb: transfusion of one RBC unit is usually ineffective. 
Clinicians seem to have adopted this rule uniformly (I, Figure 5). The practice of 
dosing with two RBC units per transfusion occasion is in concordance with other 
findings (Titlestad et al., 2001; Shapiro et al., 2003; Gombotz et al., 2007). 
Observations by Surgenor et al. (1989 and 1991) differed from ours. Their 
patients with gastrointestinal diseases or knee’ and hip-replacement received 
whole blood or RBCs according to a more linear trend. Only one-unit 
transfusions were uncommon. 
The paired use of RBCs deserves further discussion. It has been argued that 
one-unit RBC transfusion is inadequate for correcting anemia and exposes 
patients to needless risks from transfusion (Micolonghi et al., 1966; Reece and 
Beckett, 1966). Later, use of single-unit transfusions by hospital transfusion 
committees was discouraged (Grindon et al., 1985). Newer randomized study 
information suggests a lower transfusion threshold than 20 years ago (Hebert et 
al., 1999). This has led to a change of this recommendation and has been 
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supported by a retrospective study (Hebert and Fergusson, 2004; Ma et al., 
2005). Ma et al. retrospectively estimated the effect of one-unit RBC transfusion 
reaching the targeted Hb count over the range of Hb triggers from 70 to 90 g/l 
in patients transfused with one or two units of RBCs. They found that single-unit 
RBC transfusion raised Hb concentration sufficiently in most patients. For this 
reason, routine paired dosing of RBCs can be questioned. 
6.2. Dosage with fresh frozen plasma 
Here we found that FFP was also transfused in paired-unit doses (I, Figure 5). 
The observation as to paired FFP dosage is similar to that in a Danish study and 
a study on elective CABG patients in the USA (Titlestad et al., 2001; Covin et 
al., 2003). The explanation for this practice cannot be found easily and is not 
supported by transfusion guidelines. National guidelines recommend body 
weight-adjusted dosing (10-15 ml per kg). Following of this guideline would 
produce for an average-weight person (70 kg) a transfusion of three to four 
units of FFP (270 mL per one unit), not two. In clinical situations, most often 
two-unit FFP transfusions are related to reversal of the warfarin effect in 
patients unable to tolerate the full volume of the suggested dose. This clinically 
observed practice has been confirmed by a study from Australia (Hui et al., 
2005). Chowdhury et al., (2004) showed in 22 critically ill patients (of who 10 
had required no FFP) that currently guided FFP dosage (12.2ml/kg) raised 
coagulation factor levels above the targeted levels (30 IU/kg, 1 g/l for 
fibrinogen) in only one of five patients, but 33.5 ml/kg dosage achieved the 
target in all seven. 
Dara et al., (2005) retrospectively studied 115 critically ill patients with INR≥1.5 
and without active bleeding. They found that FFP transfusion corrected the INR 
value in only 36% of these patients. The median dosage of FFP was higher in 
patients whose INR was corrected than in patients in whom it was not (17 ml/kg 
vs. 10 ml/kg). 
Stanworth et.al. (2011), studying FFP use in critical care, included in their 
research 29 adult general intensive critical care units and studied 1,923 
admissions with 1,212 FFP units transfused. Their median dose was 10.8 ml/kg 
(ranging first to third quartile from 7.2 to 14.4 ml/kg). Only marginally higher 
volumes of FFP (typically just one additional FFP unit) were prescribed in 
association with bleeding and an elevated INR than for non-bleeding patients. 
Their data suggest that doses of FFP were inadequate, too small. Although the 
optimal dosage of FFP is uncertain, smaller doses do correlate with poorer 
treatment response. 
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6.3. Dosage of platelets 
PLTs were transfused most often in 8-unit doses. National guidelines 
recommend adjusting the PLT dose to the patient’s body size (1 unit per 10 kg), 
thus explaining this finding. This Finnish study result differed from Danish 
findings in which recipients were transfused in a more linear fashion (Titlestad et 
al., 2001). One comparison of three different prophylactic doses of PLTs for 
hematological thrombocytopenic patients based on body surface area had no 
effect on incidence of bleeding (Slichter et al., 2010). Similar results appeared in 
two smaller studies earlier (Tinmouth et al., 2004; Heddle et al., 2009). The 
Strategies for Transfusion of Platelets study was, however, halted because the 
study limits were reached. A 5% absolute difference in grade-4 bleeding 
(including debilitating bleeding, nonfatal central nervous system bleeding or 
fatal bleeding) between study groups was reached after enrollment of only 119 
patients. This study differed from that of Slichter et al. (2010) by its using 
standard doses of PLTs not adjusted for body-surface area. The optimal dosage 
of PLTs for prophylaxis thus remain unclear. 
7. Transfusion practices 
In orthopedic patients, the percentage of RBC-transfused patients among all 
patients undergoing knee replacement, as well as the mean number of 
transfused RBC units has fallen since the 1990s in Finland (from 84% to 33%, 
from a mean of 2.6 to 0.8 RBC units) (I; Capraro, 1998). A study from Canada 
found an even lower RBC transfusion ratio in primary knee-replacement patients 
(16.5%) (Feagan et al., 2001). Our benchmarking data published on the 
Internet shows a similar trend in RBC use for primary hip-replacement patients 
(Standard reports, database on the Internet, 2006). The decrease in Finnish 
RBC requirements in orthopedic patients may have resulted from evolved 
surgical techniques, increase in use of blood conservation methods, and a 
lowered Hb trigger for RBC transfusion. The difference from international data 
might be explained by the same variables. 
Our data included 2,910 TURP patients with an RBC transfusion rate of 10% 
(range 3-20%). Earlier data from Finland showed a transfusion percentage of 
18% with the TURP procedure (range 7-31% between hospitals) (Capraro et al., 
2000). Robertson et al. (1993) had reported a lower rate of RBC recipients 
(11%; mean 2.6 units, range 1-7). The same kind of decrease in percentage of 
transfusion recipients emerged in the Uchida et al. (1999) study; the transfusion 
rate in TURP patients in Japan decreased from 20% in 1971-1985 to 6% in 
1985-1996. 
The results of this thesis show that 8% of patients undergoing hysterectomy for 
uterine fibroids received RBCs, a transfusion rate almost twice as high as in 
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institution studies from the USA (3%) and Australia (5%) (Ng, 1997; Kohli et 
al., 2000). Differences in study sample sizes (3,967 versus 491 and 3,967 
versus 236) and dissimilarity of the institutions may also explain part of this 
dissimilarity. Conversely, Dicker et al. (1982) found a transfusion rate almost 
twice as high as in Finland (13%). 
The percentage of PLT recipients among CABG patients ranged between Finnish 
hospitals from 7 to 14% (mean 9%). This result was similar to previously 
reported data from Finland (9%, range 2-22%) and from the USA (10%, range 
4.8-18.4%) (Kytölä et al., 1998; Covin et al., 2003). Reasons for this persistent 
high rate of PLT use went unstudied. It is conceivable that improvements in PLT 
salvage based on improvements in surgical techniques, for example increase in 
off-pump CABG, are not evident because over the same time-period, anti-
platelet-agent use increased. Variability in the present study was less than in an 
earlier Finnish study by Kytölä et al. (1998), suggesting more consistent PLT 
transfusion practices within Finnish hospitals. 
8. Parturients 
The finding of RBC transfusions’ not shortening the length of hospitalization in a 
selected group of parturients suggests the possibility of unnecessary RBC 
transfusions. Dickason and Dinsmoor (1992) studied 899 patients who delivered 
by caesarean section. They found 7% of them to receive RBC transfusions 
(mean 2.8±1.4 units). Transfused patients were hospitalized longer than the 
non-transfused (mean hospital stay 6.1±3.9 versus 5.0±1.5 days, p=0.032). 
The lowest Hb and the hospital-discharge value of Hb, as well as estimated 
blood loss, differed between RBC recipients and non-transfused patients 
(respectively, lowest Hb 76±14 g/l versus 100±14 g/l; discharge Hb 94±12 g/l 
versus 100±13 g/l; estimated blood loss 1468±706 ml versus 879±198 ml). 
These study results differed from ours: their discharge Hb value was lower in 
transfused patients, disparate from our present findings. Estimated blood loss 
was almost double in transfusion recipients, and the lowest Hb values differed 
between groups. The patient groups thus differed between these two reports. 
Furthermore, a metanalysis of randomized and restrictive versus liberal RBC 
transfusion groups found no difference in length of hospital stay for Hb triggers 
between 70 and 100 g/L, agreeing with our finding (Carless et al., 2010). 
However, anemia, per se, lengthened the hospital stay of parturients in the 
present thesis study. As mentioned by Asakura et al. (2007) mere following of 
the Hb-level, even in an otherwise healthy mother, does not suffice to prevent 
unnecessary transfusions. A retrospective study based on chart review on 
obstetric in-patients in the USA found 34% of RBC-transfused mothers without 
any written indication for transfusion, with the majority of these patients (80%) 
receiving only 1 to 2 units of RBCs (Butwick et al., 2009). Findings from USA 
supports our finding suggesting inappropriate RBC transfusions in this patient 
  64 
population. Our nadir and discharge Hb values were higher than these from the 
USA, based on the difference in study populations, the US study including also 
complicated pregnancies and deliveries. 
9. Prediction of blood need 
The increasing blood need in the future calls for amendment of practices to 
avoid a blood shortage. One simple way of improving the blood use routine is to 
target blood orders to the patients needing them most. Correctly targeted blood 
orders reduce blood wastage, minimize blood storage and blood-storage times, 
reduce expenses, and enable more rapid use of blood products. 
Scoring systems to predict the massive RBC need for trauma patients have been 
developed (Yücel et al., 2006; Nunez et al., 2009; Mitra et al., 2012). German 
and Australian studies used patient variables such as gender, hemoglobin value, 
and severity of disease to estimate the need for transfusion, similarly to our 
study (Yücel et al., 2006; Mitra et al., 2012). The US study did not include 
laboratory parameters or gender and used only severity of disease and clinical 
values such as blood pressure and heart rate for prediction (Nunez et al., 2009). 
These scores designed for trauma patients performed better than our score 
system for hip arthroplasty patients, but trauma studies chose more specific 
parameters for severity of disease (free abdominal fluid, type of fracture, 
Glasgow Coma score) than the rough ASA classification in our prediction model. 
Furthermore, the patient populations in these studies differed (massively 
bleeding trauma patients versus elective hip-surgery patients). 
At the time of our study, the normal routine for hip arthroplasty surgery was an 
order of 4 units of RBCs pre-operatively. Our score could have been used in a 
clinical situation: patients with scores from 0 to 40 (predictive transfusion risk 
under 40%), order of 0 to 1 RBC units; scores from 40-80 (transfusion risk 40-
80%), order of 2 to 3 units of RBCs; patients with scores over 80 (transfusion 
risk over 80%), order of 4 units. This approach should be tested in clinical use 
before implementation. 
10. Influencing blood component use 
The present study was observational, and patient care was not standardized or 
purposely influenced in any way. However, our data-gathering system enables 
this kind of pre- and post-intervention research, and the subject of influencing 
blood component use calls for discussion. Blood component use indications have 
changed over the years, with new study information and emphasis on more 
restrictive use. Transfusion medicine specialists have put much effort into 
education and into informing transfusing personnel of changing indications. 
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Amendment of practices is, however, laborious and slow, and many different 
approaches have been tried. Blood-use guidelines (local or national), educational 
efforts (material and sessions), reminders of appropriate blood use and auditing 
(retrospective and approving transfusion requests) have been tried and studied 
(Barnette et al., 1990; Hawkins et al., 1994; Lam et al., 1997; Toy et al., 1998; 
Pentti et al., 2003; Kakkar et al., 2004; Müller et al., 2004; Hui et al., 2005; 
Rana et al., 2006; Leal-Noval et al., 2011). Two systematic reviews failed to 
determine what type of intervention might be more effective than others in 
reducing inappropriate blood use practices but concluded that “Even simple 
interventions may be effective” (Wilson et al., 2002; Tinmouth et al., 2005). 
However, in a recent metanalysis, organizational interventions concerning FFP 
usage have shown a positive impact in reducing inappropriate FFP transfusions 
(Damiani et al., 2010). The need for prospective, randomized, matched-pair-
designed studies was acknowledged. Altering blood-use habits requires from the 
personnel performing transfusions a desire to change (Tinmouth, 2007). 
Our study results we discussed first in 2004 with a small group of Finnish 
transfusion professionals involved with data gathering. Later, we organized 
sessions reporting benchmarking data to transfusionists involved with 
orthopedics, heart surgery, obstetrics, and hematological patients. The influence 
of these gatherings on study findings is possible. 
11. Clinical implications 
The optimal practice of transfusion therapy depends on three factors: blood 
donors, clinical practice, and societal forces. Availability of suitable and willing 
donors has an effect on the availability of blood components; clinical practice 
influences the amount of needed blood, and societal forces (resources, 
legislation) affect both. The optimum of transfusion practice is also location 
related and changes over time. Continuous monitoring of varying blood 
component use provides us with information on transfusion practices and 
produces data available for comparison. Knowledge of change and variation may 
serve to improve transfusion therapy. Our research database and annual data 
collection process provide Finnish healthcare professionals a foundation for 
benchmarking. More annual data on Finnish transfusion practices are vital to 
discover and to explain changing trends in blood use and to identify the best 
areas for change. Any new practice that is simple to use, and safe for patients, 
and that leaves the decision to transfuse or not up to transfusion providers may 
help us improve our transfusion practices. Evidence-based guidelines and 
patient management program including optimizing erythopoesis, reducing 
bleeding, and tolerating anemia may improve the availability of blood products 
to the aging population (Leahy, Mukhtar, 2012). 
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RBCs are transfused in two-unit pairs, but this practice of transfusing two units 
at the same time is outdated. Newly recommended lower RBC transfusion 
thresholds can be accomplished by transfusing just one RBC unit at a time. The 
decision to transfuse RBCs can be made individually, and if patients tolerate 
anemia, clinicians can, too. 
FFP is transfused also in two-unit pairs. Transfusing FFP should be guided by 
coagulation parameters to assess the efficacy of treatment. An insufficient 
number of coagulation measurements are taken at the moment suggesting use 
of FFP as volume replacement. 
PLT transfusions are common also perioperatively; not only hematological 
patients receive PLTs. Gastrosurgical patients and heart surgery patients most 
often receive PLTs perioperatively, making them an easy choice for 
improvement efforts for PLT use. Transfusion of PLTs is guided mostly by 
measuring PLT count in surgical patients. 
Unnecessary blood ordering prolongs the storage time of blood components and 
strains the decreasing future blood supply. All efforts to minimize unnecessary 
blood orders and possible wastage of blood components improve patient care. 
12. Future perspectives 
Although improvements in care and implementation of blood salvage protocols 
reduce the need for transfusions, this trend is counteracted by the change in 
demography of the patient populations. Aging of the Finnish population leads to 
increased future need for blood components, especially for RBCs. To provide for 
the increasing requirement, requires more dedicated blood donors. Recruiting 
new donors from the decreasing eligible population will be the upcoming 
challenge for blood-collection organizations. Demand for safer blood products 
further raises the future costs of blood transfusion therapy. Artificial oxygen 
carriers are under constant research but most likely will not replace RBCs in the 
near future. 
A PLT transfusion increase is expected. A growing number of intensive treatment 
regimens for hematological and other malignancies and increasing use of new 
anti-platelet drugs will raise the number of PLT recipients, as will the aging 
population. FFP use may, on the other, hand decrease or at least even out. 
Coagulation factor-concentrate therapy seems to be increasing as products 
improve and prices become comparable. Easy accessibility and low infection risk 
makes these coagulation concentrates attractive. Furthermore, the use of point-
of-care coagulation tests is increasing, facilitating the use of these concentrates. 
Scientific evidence on their efficacy and safety is essential. 
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A need is widely acknowledged for randomized, controlled studies to optimize 
transfusion therapy practice. Clinical studies on effectiveness, appropriate 
dosage, and transfusion-trigger values for FFP and PLT use are crucial. 
Additional Finnish transfusion data has been gathered and reported on the FRC 
BS Internet pages. Improvement of this kind of transfusion database includes 
adding more parameters, such as patient’s weight and height, point-of-care 
measurement values, use of anticoagulation, indication for transfusion, and 
blood loss, when such data are entered into hospital computerized registers. 
Combining hospitals’ transfusion-recipient information with FRC BS blood unit 
information, which is technically possible at the moment, would help in 
evaluating the relation between the age of blood units and morbidity or 
incalculating the wastage of blood products. Hopefully, an enthusiastic group of 
physicians with special interest in transfusion therapy will form, combine their 
research data, and share transfusion-related information. 
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CONCLUSIONS 
Data on hospital electronic systems can be combined and used to study 
transfused patients and transfusion practices. 
1. The variability still evident in Finnish transfusion practices between hospitals 
is suggestive of inappropriate use of blood components. The practice of 
transfusing RBCs in two-pair units is questionable. Newly published data 
recommend lower hemoglobin thresholds for RBC transfusion, which can be 
accomplished in certain situations by transfusing only one RBC unit. 
2. FFP use is not optimal in Finland. A large amount of FFP is transfused without 
the guidance of coagulation tests. This suggests the use of FFP as volume 
replacement, a practice not recommended by current guidelines. 
3. Even though the length of hospitalization for anemic parturients is longer than 
normal, transfusion of 1 to 2 units of RBCs to a mildly anemic (Hb value 
between 70 and 100 g/l), healthy parturient does not shorten her 
hospitalization. This finding supports the current RBC transfusion policy. 
4. Although only about 1% of surgical patients receive PLTs, patients undergoing 
gastric and heart surgery are two of the largest groups of PLT receivers. These 
patient groups are good targets for PLT use-optimizing efforts. 
5. In surgical patients, preoperative morbidity as estimated from the ASA grade 
assigned correlates with their transfusion requirement. This correlation is more 
evident in single hospitals than in the combined Finnish data. This information 
may be useful in optimizing blood order practices. 
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YHTEENVETO JA JOHTOPÄÄTÖKSET 
Aikaisemmissa tutkimuksissa, myös Suomessa tehdyissä, on todettu monin-
kertaisia eroja verivalmisteiden käytössä samanlaisilla potilasryhmillä. Löydös 
viittaa siihen, että verensiirtokäytännöt eivät ole kaikkialla optimaalisia. 
Suomalaisten sairaaloiden tietojärjestelmissä on talletettuna paljon tietoa veren-
siirroista ja niiden saajista. Tämän tutkimuksen tarkoituksena oli luoda jatkuva, 
sairaaloiden eri tietojärjestelmiä hyväkseen käyttävä tietojenkeräysjärjestelmä, 
jolla suomalaisia verensiirtokäytäntöjä voitaisiin seurata ja tutkia. 
Tutkimukseen osallistui yhteensä 10 suomalaista sairaanhoitopiiriä (5 yliopisto- 
ja 5 keskussairaalajohtoista sairaanhoitopiiriä). Tiedot kerättiin vuosien 2002-
2005 välillä. Tietovarastoon kerättiin tietoja verivalmisteiden käytöstä 
sairaaloiden potilashallintojärjestelmistä, verikeskusjärjestelmistä, laboratorio- 
järjestelmistä ja toimenpidetietojärjestelmistä. Tietojärjestelmien tiedot yhdis-
tettiin tietovarastoon sairaalahoitojaksoiksi tunnistamattomaksi koodatun 
henkilötunnuksen avulla. 
Tietovaraston laadunvarmistuksella todettiin kerätyn tiedon laadun riittävän 
vertailutarkoitukseen. Laadunvarmennuksessa 96.8% sairaanhoitopiireissä 
käytetyistä aikuisten verivalmisteista yhdistyi toimittajan, Suomen Punaisen 
Ristin Veripalvelun, myyntitietoihin. Sairaaloiden välillä todettiin edelleen 
vaihtelua verensiirtojen määrissä ja verivalmisteita saaneiden potilaiden 
osuuksissa leikkauspotilailla. Esimerkiksi punasoluja saaneiden 
polviproteesileikkauspotilaiden osuus vaihteli 12% ja 57% välillä sairaalasta 
riippuen. Verivalmisteita saaneet potilaat olivat tavallisesti iäkkäitä; yli 50% 
verivalmisteista annettiin yli 65-vuotiaille. Tavallisin verta saanut potilas oli yli 
65-vuotias nainen, jolle oli annettu 2 yksikköä punasoluja. N.10% veri-
valmisteita saaneista oli lapsia. Punasoluja ja jääplasmaa annosteltiin yleensä 
kahden yksikön erissä. Yli 60% käytetystä jääplasmasta siirrettiin kirurgisille 
potilaille, joista noin 25% annettiin sydän- ja verisuonileikkausten yhteydessä. 
Hyytymistekijätutkimuksia ei tehty kaikkien jääplasmasiirtojen yhteydessä, jopa 
kolmasosa käytetystä jääplasmasta annettiin ilman tietoa hyytymistekijä-
pitoisuuksista. Suomessa käytettiin n. 400 punasolu- ja n. 100 jääplasma-
yksikköä per 1 000 leikkaushoitojaksoa. Lievästi aneemisilla synnyttäjillä 0-2 
yksikön punasolusiirto ei vaikuttanut sairaalahoitojakson pituuteen. Aneemisten 
äitien sairaalahoidon pituus oli kuitenkin keskimääräistä huomattavasti pidempi 
(5.2 päivää verrattuna keskimääräisen synnyttäjän 3.5 päivää) verensiirrosta 
riippumatta. Suurin osa verihiutaleista (43%) annettiin veritautipotilaille. Vain 
1% leikkauspotilaista sai verihiutaleita. Kuitenkin yli puolet (54%) verihiutaleita 
saaneista potilaista oli kirurgisesti hoidettuja. Verihiutaleita saavien 
leikkauspotilaiden sairaalakuolleisuus oli korkea: leikkausten yhteydessä 
verihiutaleita saaneista potilaista menehtyi sairaalahoitojakson aikana 13.1%, 
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kun taas kaikista verihiutaleita saaneista menehtyi vain 9.5%. Leikkauspotilailla 
perussairauksien puolesta sairaimmat saivat eniten verivalmisteita leikkausten 
yhteydessä. Esimerkiksi ASA 3 ja 4 luokan potilaille (sairaimmaksi luokitellut 
potilaat) annettiin lähes 70% leikkausten yhteydessä käytetyistä 
verivalmisteista. Tätä tietoa voitiin käyttää arvioitaessa lonkkaproteesileikkaus-
potilaan verivalmisteiden tarvetta ennen leikkausta. 
Verivalmisteiden käyttö Suomessa ei ole aina optimaalista. Verensiirtokäytännöt 
vaihtelevat edelleen merkittävästi leikkauspotilailla terveydenhuollon eri 
yksiköiden välillä ja lisäksi punasolujen siirto kahden yksikön erissä on 
kyseenalaista. Usein tapahtuva jääplasman siirto ilman hyytymistekijä-
tutkimuksia ei ole nykyohjeiden mukaista. Lievästi aneemisilla, mutta muuten 
terveillä synnyttäjillä 1-2 yksikön punasolusiirto ei lyhentänyt heidän muutenkin 
normaalia pidempää sairaalahoitoaikaansa. Nämä potilaat voisivat hyötyä 
punasolusiirroista pidättäytymisestä. Verihiutaleiden käytön  optimointi tulisi 
suunnata sellaisiin potilasryhmiin, joille verihiutaleita siirretään paljon, kuten 
veritautipotilaat, sekä gastrokirurgiset ja sydänkirurgiset potilaat. Kaiken-
kaikkiaan verivalmisteita siirretään usein perussairaille potilaille.  
Tutkimuksessa saatua tietoa verensiirron saajista, hoitokäytäntöjen eroista sekä 
niiden vaikutuksista voidaan käyttää hyväksi verensiirtokäytäntöjä 
optimoitaessa. 
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APPENDIX 
Details of previous studies on blood transfusion epidemiology. 
1. Appendix 1 
Transfused blood components by medical specialty. ND=no data. 
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2. Appendix 2 
Transfused blood components by age. ND=no data. 
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Transfused blood components by age (continued). ND=no data. 
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3. Appendix 3 
Transfused blood components by gender. ND=no data. 
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Transfused blood components by gender (continued). ND=no data. 
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4. Appendix 4 
Transfused blood components by diagnostic groups. ND=no data. 
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Transfused blood components by diagnostic groups (continued). ND=no data. 
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5. Appendix 5 
Transfusions recipients' most frequent single ICD-diagnoses. 
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6. Appendix 6 
Transfusion recipients' most common surgical procedures. ND=no data. 
 
 
